header logo image


Page 1,112«..1020..1,1111,1121,1131,114..1,1201,130..»

Genetics – Genetic inheritance – NHS Choices

August 4th, 2016 9:41 am

Each cell in the body contains 23 pairs of chromosomes. One chromosome from each pair is inherited from your mother and one is inherited from your father.

The chromosomes contain the genes you inherit from your parents. There may be different forms of the same gene called alleles.

For example, for the gene that determines eye colour, you may inherit a brown allele from your mother and a blue allele from your father. In this instance, you will end up with brown eyes because brown is the dominant allele. The different forms of genes are caused by mutations (changes) in the DNA code.

The same is true for medical conditions. There may be a faulty version of a gene that results in a medical condition, and a normal version that may not cause health problems.

Whether your child ends up with a medical condition will depend on several factors, including:

Genetic mutations occur when DNA changes, altering the genetic instructions. This may result in a genetic disorder or a change in characteristics.

Mutations can be caused by exposure to specific chemicals or radiation. For example, cigarette smoke is full of chemicals that attack and damage DNA. This causes mutations in lung cell genes, including the ones that control growth. In time, this can lead to lung cancer.

Mutations can also occur when DNA fails to be copied accurately when a cell divides.

Mutations can have three different effects. They may:

Some medical conditions are directly caused by a mutation in a single gene that may have been passed onto a child by his or her parents. These are known as monogenic conditions.

Depending on the specific condition concerned, monogenic conditions can be inherited in three main ways. These are outlined below.

For conditions that are inherited in an autosomal recessive pattern to be passed on to a child, both parents must have a copy of the faulty gene (they are carriers of the condition).

If the child only inherits one copy of the faulty gene, they will be a carrier of the condition but will not have the condition themselves.

If a mother and a father both carry the faulty gene, there is a one in four (25%) chance of each child they have inheriting the genetic condition and a one in two chance (50%) of them being a carrier.

Examples of genetic conditions inherited in this way include:

For conditions that are inherited in an autosomal dominant pattern to be passed on to a child, only one parent needs to carry the mutation.

If one parent has the mutation, there is a one in two (50%) chance it will be passed on to each child the couple has.

Examples of genetic conditions inherited in this way include:

Some conditions are caused by a mutation on the X chromosome (one of the sex chromosomes). These are usually inherited in a recessive pattern albeit in a slightly different way to the autosomal recessive pattern described above.

X-linked recessive conditions often don't affect females to a significant degree because females have two X chromosomes, one of which will almost certainly be normal and can usually compensate for the mutated chromosome. However, females who inherit the mutation will become carriers.

If a male inherits the mutation from his mother (males cannot inherit X-linked mutations from their fathers because they will receive a Y chromosome from them), he will not have a normal copy of the gene and will develop the condition.

Whena mother is a carrier of an X-linked mutation, each daughter they have has a one in two (50%) chance of becoming a carrier and each son they have has a one in two (50%) chance of inheriting the condition.

When a father has an X-linked condition, his sons will not be affected because he will pass on a Y chromosome to them. However, any daughters he has will become carriers of the mutation.

Examples of genetic conditions inherited in this way include:

Although genetic conditions are often inherited, this is not always the case. Some genetic mutations can occur for the first time when a sperm or egg is made, when a sperm fertilises an egg, or when cells are dividing after fertilisation. This is known as a 'de novo' or 'sporadic' mutation.

Someone with a new mutation will not have a family history of a condition, but they may be at risk of passing the mutation on to their children. They may also have, or be at risk of developing, a form of the condition themselves.

Examples of conditions that are often caused by a de novo mutation include some types of muscular dystrophy, haemophilia and type 1 neurofibromatosis.

Some conditions are not caused by a mutation on a specific gene, but by an abnormality in a person's chromosomes such as having too many or too few chromosomes, rather than the normal 23 pairs.

Examples of conditions caused by chromosomal abnormalities include:

While these are genetic conditions, they are generally not inherited. Instead, they usually occur randomly as a result of a problem before, during, or soon after the fertilisation of an egg by a sperm.

Very few health conditions are only caused by genes most are caused by the combination of genes and environmental factors. Environmental factors include lifestyle factors, such as diet and exercise.

Around a dozen or so genes determine most human characteristics, such as height and the likelihood of developing common conditions.

Genes can have many variants, and studies of the whole genome (the whole set of genes) in large numbers of individuals are showing that these variants may increase or decrease a persons chance of having certain conditions. Each variant may only increase or decrease the chance of a condition very slightly, but this can add up across several genes.

In most people, the gene variants balance out to give an average risk for most conditions but, in some cases, the risk is significantly above or below the average. It is thought that it may be possible to reduce the risk by changing environmental and lifestyle factors.

For example, coronary heart disease (when the heart's blood supply is blocked or interrupted) can run in families, but a poor diet, smoking and a lack of exercise can also increase your risk of developing the condition.

Research suggests that in the future it will be possible for individuals to find out what conditions they are most likely to develop. It may then be possible for you to significantly reduce the chances of developing these conditions by making appropriate lifestyle and environmental changes.

The two strands of DNA are wound around each other into a double helix

Page last reviewed: 07/08/2014

Next review due: 07/08/2016

Continue reading here:
Genetics - Genetic inheritance - NHS Choices

Read More...

Department of Genetics at Washington University St. Louis

August 4th, 2016 9:41 am

Samantha comes to us from Boston Childrens Hospital and Harvard Medical School where she has been a postdoctoral...

posted on: Jun 4, 2015 | author: admin

Geneticists seek to understand how genes are inherited, modified, and expressed. Geneticists have been remarkably...

posted on: Dec 5, 2013 | author: admin

View progress of the new Genetics Building

posted on: Dec 5, 2013 | author: admin

The Genome Engineering and IPSC Center (GEiC) was formed by the consolidation of two pre-existing cores, the Genome...

posted on: Dec 5, 2013 | author: admin

Washington University School of Medicine in St. Louis plans to construct an energy-efficient, multistory research...

posted on: Dec 5, 2013 | author: admin

Gautam Dantas, PhD, has won a prestigious National Institutes of Health award for innovative research that may improve...

posted on: Apr 18, 2013 | author: admin

Barak A. Cohen, PhD, and Robi D. Mitra, PhD, have been named Alvin Goldfarb Distinguished Professors of Computational...

posted on: Sep 4, 2012 | author: WUSTL School of Medicine News

The Department of Genetics is at the forefront of the rapidly developing field known as Genomic (or Personalized)...

posted on: Aug 22, 2012 | author: admin

Genetic errors identified in a new study led by Washington University School of Medicine in St. Louis may reduce risk...

posted on: Mar 3, 2016 | author: admin

Sarah Garwood, MD, an assistant professor of pediatrics at Washington University School of Medicine in St. Louis,...

posted on: Feb 25, 2016 | author: admin

Using a laser probe, neurosurgeons at Washington University School of Medicine in St. Louis have opened the...

posted on: Feb 24, 2016 | author: admin

Worldwide, an estimated 25 percent of children under age 5 suffer from stunted growth and development. The most...

posted on: Feb 23, 2016 | author: admin

See the original post here:
Department of Genetics at Washington University St. Louis

Read More...

Human Genetics – Population Genetics

August 4th, 2016 9:41 am

for 1st YEAR STUDENTS INTRODUCTION

he applications of Mendelian genetics, chromosomal abnormalities, and multifactorial inheritance to medical practice are quite evident. Physicians work mostly with patients and families. However, as important as they may be, genes affect populations, and in the long run their effects in populations have a far more important impact on medicine than the relatively few families each physician may serve. It is important that certain polymorphisms are maintained so that the species may survive, even at the expense of individuals. Genetic polymorphisms often are detrimental to the homozygote, but they allow others of the species to survive. Before medical intervention was possible, populations that lacked the sickle cell anemia allele could not survive in the malaria regions of West Africa. Those that had the sickle cell anemia allele survived, and the gene remains in the population at high frequency today, even though the homozygous recessive phenotype was at a severe disadvantage in the past. The high rate of thalassemia in people of Mediterranean origin, the high rate of sickle cell anemia in people of West African descent, the high rate of cystic fibrosis in people from Western Europe, and the high rate of Tay-Sachs disease in ethnic groups from Eastern Europe may all owe their origin to environmental factors that cause changes in gene frequencies in large populations by giving some advantage to heterozygotes who carry a deleterious allele. Although one may never use the calculations of population genetics in medical practice, the underlying principles should be understood.

Population genetics is also the most widely misused area of human genetics, sometimes bordering on "vigilante genetics," a term coined by Newton Morton. Persons have mistakenly applied population genetics to "prove" race superiority for intelligence and aptitudes, and have misused it in eugenics. As an educated and, I hope, a respected member of your community you must be alert to "vigilante genetics."

Population genetics is concerned with gene and genotype frequencies, the factors that tend to keep them constant, and the factors that tend to change them in populations. It is largely concerned with the study of polymorphisms. It directly impacts counseling, forensic medicine, and genetic screening.

Consider a population of 1000 individuals all typed for the simplest test at the MN blood group locus. At its most simplistic form this locus can be reduced to a codominant system with two alleles M and N. (In reality it is considerably more complex than this but this simple form will suffice for our examples.) Every individual in the population will be either M (having two M alleles), MN (heterozygous), or N (having two N alleles). Suppose the blood typing results were as follows: 300 M individuals, 600MN individuals, and 100 N individuals. You probably want to ask, "What is the gene frequency of the M allele in the above population of 1000 individuals?" I'm glad you're interested!

1000 individuals each have two alleles at the MN locus = 2000 genes

Each M individual has 2 M alleles 300 x 2 = 600 M alleles

Each MN individual has 1 M allele 600 x 1 = 600 M alleles

There is a total of 1200 M genes in a population of 2000 genes. The gene frequency of the M allele is 1200/2000 = 0.6

I'll bet you want to know, "What is the gene frequency of the N allele?" Well, I'll show you how to find out.

Each MN individual has 1 N allele 600 x 1 = 600 N genes

Each N individual has 2 N genes 100 x 2 = 200 N genes

Again, there is a total of 2000 genes in the population for the MN locus. The gene frequency of the N allele is 800/2000 = 0.4

Notice that when there are only two alleles in the population, their gene frequencies must add to 1. If they don't, you've done something wrong. This counting method of calculating the gene frequency must be used whenever the heterozygote can be detected.

Gene frequency = (2 x homozygote + heterozygote) / 2 x population

Gene frequency for one allele = 1 - gene frequency of the other allele

These two general formulas assume nothing of the population, only that it is a single interbreeding group. All other methods make some assumptions of the population in order to simplify calculations.

For many human autosomal recessive traits the heterozygote cannot be distinguished from the normal homozygote. When this occurs the Hardy-Weinberg equilibrium is assumed to apply. These authors, Hardy in England and Weinberg in Germany, used different approaches but came to the same conclusions in 1908. They made several assumptions of the population:

Under these assumptions, Hardy and Weinberg found that the gene frequency and the genotype frequency in the population do not change from generation to generation. Furthermore, if the frequency of the dominant allele A in the founding population was p , and the frequency of the recessive allele a in the founding population was q, then after one generation of random mating the genotype frequencies would remain fixed and would be in the ratio:

If you want to see evidence that this is true, see Figure 20. If, on the other hand, you believe everything you read, and only want to study what will be covered on the examination, continue on.

Hopefully, someone will ask the question, "Is there any evidence that the human population meets the requirements of Hardy-Weinberg equilibrium, or is this just a mental exercise?" Of course there is evidence! Consider the following:

In my experience, one may use several criteria for selecting a person to mate with, but one usually doesn't select a mate based on blood types at the MN blood group locus. Therefore, we might assume that this locus would be a good test of random mating. All of the other Hardy-Weinberg criteria also seem to be met. Mutations at this autosomal locus are rare. We know of no selective advantage or disadvantage in the present environment. And migration wouldn't be much of a factor if we took the sample at one short interval of time. This locus should provide a good test.

We have already seen that gene frequencies and genotype frequencies for this locus can be determined without using assumptions of Hardy-Weinberg equilibrium. Let's see if a real population sample is distributed as p2 (M), 2pq (MN), q2 (N).

In 1975, Race and Sanger reported the typing results from 1279 individuals in London. They were not collecting these data for the purpose of testing for Hardy-Weinberg equilibrium, so they could not be accused of typing individuals until a certain distribution was achieved, a question that has always remained about Mendel's original studies. Race and Sanger found 363 persons were M, 634 were MN, and 282 were N. Using our original method of calculating gene frequencies, the frequency of the M allele (p) would be:

p = (2 x 363) + 634 / (2 x 1279) = 0.53167

The frequency of the N allele (q) would be:

q = (2 x 282) + 634 / (2 x 1279) = 0.46833

If the population were in Hardy-Weinberg equilibrium, then the number of M individuals should be p2 x 1279, the number of MN individuals should be 2pq x 1279, and the number of N individuals should be q2 x 1279, or

For the MN blood group locus there can be little doubt that the conditions for Hardy-Weinberg equilibrium are met in the human population, at least the population in London where the sample was taken. The observed frequencies closely approximate what would be expected if the population were in Hardy-Weinberg equilibrium.

This gives us the assurance that we can use Hardy-Weinberg as a method when the heterozygote cannot be detected. An example of the use of the Hardy-Weinberg principle in medical genetics is given below.

Suppose there is an autosomal recessive disease where the frequency of affected in the population is 1/10,000. If the population is in Hardy-Weinberg equilibrium, this frequency would equal q2. The gene frequency of the recessive allele (q) would then be the square root of q2, or the square root of 1/10,000 which equals 1/100. The carrier (heterozygote) frequency (2pq) is usually approximated as 2q since p (0.99) is so close to 1. The carrier frequency is then 1/50.

For an autosomal recessive disease with a population frequency of 1/10,000, the carrier frequency is 1/50. Put another way, on average, as many as 3 or 4 first year medical students at UIC are carriers of such a disease.

From time to time, certain groups have suggested that the way to eliminate a deleterious disease from the population is to not allow affected individuals to mate. The above example should provide some evidence that this will have little effect on gene frequencies in the population. Although the frequency of the disease is only 1/10,000, (we should have one affected first year medical student at UIC every 50 years) the carrier frequency is 1/50 (we should have 3 or 4 carriers at UIC in every incoming class). These phenotypically normal carriers will keep the gene in the population.

If, by chance, a student in the first year class has a sibling with an autosomal recessive disease that is present at birth, the student would have a 2/3 chance of being a carrier. If that student were to have a child with an unrelated partner selected at random from the general population, and the disease frequency in the general population is 1/10,000, the probability of their child being affected is:

Compare that to the probability that two unrelated individuals, with no history of the disease in their families would have an affected child, when the carrier frequency is 1/50:

Since it is a stated goal of medicine to do what is best for the patient, what happens to genes in populations when exceptions to Hardy-Weinberg occur?

Although mutation rates are usually very low, geneticists have long been concerned about environmental factors that will lead to even slight increases. There are two general types of mutation, a mutation that changes a gene that makes a functional product into a gene that makes a nonfunctional product (forward mutation) and a mutation that changes a gene that makes a nonfunctional product into a gene that makes a functional product (reverse mutation). Several events can lead to a forward mutation, base change, base insertion, base deletion, etc., but a reverse mutation must correct the specific change that produced the original forward mutation. For example if a single base deletion caused the original forward mutation, then that base must be re-inserted in exactly the same place for a reverse mutation to occur. In general, forward mutations occur at a frequency that is at least 10 times that of reverse mutations. A method of estimating forward mutation rates is given in Gelehrter, Collins, and Ginsburg, 2nd ed., Chapter 4. Students will be well advised to read this chapter carefully.

If is the forward mutation rate from a functional to a nonfunctional allele, and is v the reverse mutation rate from a nonfunctional allele to a functional allele at the same locus, an equilibrium will be established between these two mutation rates that determines q, the gene frequency of the nonfunctional allele.

At equilibrium, q = /(+v)

If v is truly one tenth the frequency of , then we can assign the value 1 for v and 10 as the value for . The above equation reduces to

qequil = 10/(10+1) or 10/11 =0.90909090909

Gene frequencies for nonfunctional alleles tend to increase in the population because of recurrent mutation. They will not entirely eliminate functional alleles but they tend to replace them, and can, if no other factors are involved, reach very high frequencies.

As a possible human example of the effects of recurrent mutation consider the following. In the ABO blood group system, there are two functional alleles, A and B. Alleles A and B control transferase enzymes that connect the proper sugar molecule (glucosamine or n-acetyl glucosamine) to a common precursor substance. Most likely, B was the result of arare mutation of the A allele. O is a nonfunctional allele that recognizes no substrate, and no sugar molecule is transferred, leaving the precursor unchanged. In the ABO system, O is now the most frequent allele. If there is no selective advantage, O should continue to increase at the expense of A and B.

The derivations of the equations used to calculate the effects of recurrent mutation are shown in Figure 21. Again, if you are interested only in studying for possible test questions, this material is not required.

Assume a population of N individuals with two alleles at a locus, D with a frequency of p and d with a frequency of q. At generation 0 there will be 2Np D alleles , or 2N(1-q) D alleles, and 2Nq d alleles. Assume D mutates to d at a frequency of and that d mutates to D at a frequency of v. Assume that is 10 times as frequent as v. Then at generation 1 the number of d alleles (2Nq1) would be:

2Nq1 = 2Nq (from gen. 0) + 2N (1-q) (mutations from D to d) - 2Nqv (mutations from d to D)

This reduces to:

q1 = q + (1-q) - qv Or the change in q = q1 - q or the change in q = q + (1-q) - qv - q

At equilibrium the change in q = 0, so at equilibrium 0 = q +(1-q) -qv -q, or, qv = (1-q), or, qv = - q

This reduces to q (at equilibrium) = /(+v)

One factor assumed in the discussion of recurrent mutation was that the nonfunctional allele and the functional allele have the same selective advantage. This may be true of the ABO blood group system, but it is not usually true of autosomal recessive diseases. The disease state, by definition, is always a deleterious phenotype. In autosomal recessive diseases the phenotype is almost always the result of nonfunctional alleles in the homozygous state. If left untreated the recessive phenotype for a disease would be less fit than the heterozygote or normal homozygote. How does selection against the homozygous recessive individual affect gene frequencies in the population?

Fitness, to a geneticist, is not the same as fitness to a movie director or a sports columnist. Fitness is not measured by physical attributes, it is measured by the number of offspring produced in the next generation that survive and reproduce. In a hunting-gathering society, the most fit person may have been the near sighted male who could not go on the hunt because he would stumble and make too much noise. If he were left behind to gather fruit and berries with the women, he may have become the most fit person in the tribe. Grandchildren, great-grandchildren, etc., are the best measures of the fitness of an individual. This has alway been my favorite explanation of why so many of us are near sighted, and why society changed from hunting-gathering to agriculture. It's all population genetics!

The most fit phenotype in the population is assigned a fitness of 1. If there are two equally fit phenotypes, each is assigned a fitness of 1. Those less fit must be assigned a fitness of less than 1. The difference between 1 and the fitness value is called the selection coefficient. The relationship between fitness, w, and the selection coefficient, s, is given by the equation, w = 1-s. The textbook uses f as the symbol for fitness, although historically most geneticists reserve f as the symbol for the inbreeding coefficient and use w as the symbol for fitness.

The effect of selection against the recessive phenotype is that, no matter how little the selection coefficient, as long as s is not 0, recessive alleles will be lost at each generation until no more remain in the population. Selection tends to reduce nonfunctional recessive alleles from the population; recurrent mutation tends to create nonfunctional recessive alleles in the population. The derivations of the effects of selection against the recessive phenotype are shown if Figure 22. Again, the material in Figure 22 will not be examined in this course.

The frequency of q in generation 1, q1, = (2 x homozygote + heterozygote)/ 2 x total

q1 = [2(1-s)q2 + 2pq]/ 2(1-sq2) , and q, the change in q, = q1 - q

q = [(1-s)q2 + (1-q)q]/ (1-sq2) , which reduces to q = [-spq2]/ (1-sq2)

q = 0 only when q = 0. There will be no equilibrium until the recessive allele is eliminated.

Since mutation tends to increase nonfunctional alleles in the population, and selection against the recessive phenotype tends to remove them, is there a point where these two will reach an equilibrium where gene frequencies remain stable from generation to generation? Again, if is the mutation rate, and s is the selection coefficient, an equilibrium will be reached when

= sq2

If the fitness of the homozygous recessive individual is 0, that is, the individual with that phenotype cannot reproduce, then s equals 1 and the above equation reduces to

= q2

The disease frequency cannot go lower than the recurrent mutation rate, even if affected individuals cannot reproduce.

The derivations of these equations are shown in Figure 23.

For mutation, the change in q = - q -qv. For selection, the change in q = [-spq2]/ [1-sq2]. If they balance at an equilibrium, the net effect is that they should sum to 0.

- q - qv + ([-spq2]/[1-sq2]) = 0

To simplify calculations, we will get rid of second order variables (qv) is only 1/10 of (q) and can be eliminated. Similarly, sq2 is very small in the denominator when compared to 1, and can be eliminated. This reduces the equation to

-q - spq2 = 0 to first order magnitude.

This reduces to - q = s(1-q) q2 or (1 - q) = (1-q)sq2

At equilibrium, = sq2 to first order magnitude.

Some genes exist at a rather high frequency in the population because the heterozygote is more fit than either homozygote. The only documented example of this is sickle cell anemia in Western Africa. There are three major genotypes for the sickle cell locus, each producing a different phenotype, in West Africans, AA, or normal individuals, AS or heterozygote individuals (often called carriers), and SS individuals who will have sickle cell anemia. Without medical intervention, SS individuals will have a fitness less than 1. In the falciparum malarial environment of West Africa, AA and AS individuals get malaria, but AS individuals usually have much milder cases of the disease and usually survive while AA individuals are less likely to do so. The heterozygote is the most fit phenotype of the three. If the selection coefficient against the homozygous normal AA individual is t, and the selection coefficient against the homozygous SS individual is s, and if p is the frequency of the A allele and q the frequency of the S allele then an equilibrium will be reached in which

p = s/(s + t) and q = t/(s + t). The gene frequencies at equilibrium are determined only by the relative sizes of the selection coefficients, not by their absolute magnitudes.

The derivations of these formulas are shown in Figure 24. Again, you are not responsible for knowing how to derive these formulas.

The gene frequency of the q allele at generation 1, q1 = [2pq + 2q2(1-s)]/2[1- tp2 - sq2]

Again the change in q, q, = q1 - q and at equilibrium, q = 0

0 = [pq + (1-s)q2/ [1-tp2-sq2] Substituting (1- q) for p, this equation will reduce to:

0 = -spq + tp2 or sq = tp

When (1-q) is substituted for p or (1-p) is substituted for q, this reduces to:

q = t/(s + t) and p = q/(s + t).

Assortive mating in humans may occur to a limited degree for traits such as intelligence. In some studies, married couples have higher correlation coefficients for intelligence than do siblings. In modern western culture, we tend to marry someone who is about our own intelligence, although this is probably an over simplification. If intelligence were controlled by a single genetic locus with two alleles, S for smart and D for dumb, then three phenotypes would be possible, SS for smart persons, SD for persons with average intelligence, and DD for persons who are mentally challenged. Of course, we know that intelligence is a multifactorial trait and not a single gene trait, but it is interesting to see what happens if it were a single gene trait with assortive mating where smart persons were only allowed to mate with smart persons, average persons with average persons, and mentally challenged only with mentally challenged. Strangely enough the gene frequencies do not change, only the genotype frequencies. The results are shown in Figure 25.

Two different populations result, one smart, the other mentally challenged. Average gets lost. Assortive mating eventually results in two species being formed from one.

Gene frequencies in small isolate populations do not reflect those of the larger founding population from which they were derived because of two factors, founder effect and random genetic drift. Founder effect occurs when the population grew from a few founding individuals. A few individuals cannot represent all of the genomes of the founding population. As we discussed before, each of us is carrying from 1 to 8 mutant genes in the heterozygous state, even though we are normal. When the founding population is small, intermarriage must result even though steps are taken to avoid it. The mutations carried by the founders are in higher frequency than they would be in the general population from which the founders came. Island populations founded by pirates or shipwreck, that were isolated for several generations tend to have different gene and genotype frequencies because of founder effect. Similarly, religious isolates, where marriage outside the religion is forbidden, also have founder effects.

Even if the founders of small isolate populations had exactly the same genotypes and gene frequencies of the original parent population, gene and genotype frequencies would change because of random genetic drift. Random genetic drift occurs because a small population cannot maintain randomness. Consider a population with 10 individuals with only two alleles at a locus, D with a frequency of 0.5 and d with a frequency of 0.5. By chance alone one would expect to find 10D and 10 d gametes being passed to the next generation. But one may find 11 D and only 9 d gametes. The next generation, one could find 10 and 10 again, or could find 12 and 8. But suppose after drifting to 12 D and 8 d, by chance a really skewed sampling occurred and one got 15 D and 5 d. It would be difficult, if not impossible to get back to the original 10D and 10 d. Sampling errors in small populations are always going to occur if given enough opportunities. These errors assure that random genetic drift will always occur. Isolate populations never have the same gene and genotype frequencies as their founding populations.

It is obvious that the major difference between autosomal loci and X-linked loci in populations is that the males (usually half the population) have only one X. Males cannot have the distribution, p2, 2pq, and q2 because they have only one X, they have either the normal allele p, or the recessive allele, q. In males, gene and genotype frequencies are the same. Thus, the genotype frequencies in the male and female can never be the same. In addition, there can be no heterozygote x heterozygote mating class since there are no male heterozygotes, and as of this date females cannot mate and produce a child. X-linked traits can reach stable gene frequencies in males and females, but cannot reach Hardy-Weinberg equilibrium.

[Return to top of this page] or [Return to the Course Outline]

Once the Mallard page loads you can access the quizzes by clicking on the Lessons Page link (also the third icon from the top of the navigation bar) or the Current Lesson link (also the fourth icon from the top of the navigation bar).

Contact Dr. Robert Tissot with questions about the content of these pages.

Contact Dr. Elliot Kaufman, Course Director with questions about the functionality of these pages.

More here:
Human Genetics - Population Genetics

Read More...

Gene Therapy News — ScienceDaily

August 4th, 2016 9:41 am

In Lung Cancer, Not All HER2 Alterations Are Created Equal Jan. 28, 2016 Study shows two distinct causes of HER2 activation in lung cancer: mutation of the gene and amplification of the gene. In patient samples of lung adenocarcinoma, 3 percent were found to have HER2 ... read more Dec. 12, 2015 Results from a long-term clinical trial conducted by cancer researchers show that combining radiation treatment with 'suicide gene therapy' provides a safe and effective one-two punch ... read more Gene Therapy Used to Extend Estrogen's Protective Effects on Memory Dec. 8, 2015 The hormone estrogen helps protect memory and promote a healthy brain, but this effect wanes as women age, and even estrogen replacement therapy stops working in humans after age 65. Now researchers ... read more Shrinking Tumors With an RNA Triple-Helix Hydrogel Glue Dec. 7, 2015 An efficient and effective delivery vehicle for gene therapy has been developed by researchers who have used it to shrink tumors by nearly 90 percent in a pre-clinical model of triple-negative breast ... read more Characteristics That May Increase a Breast Cancer Survivor's Risk of Developing Leukemia Following Treatment Identified Dec. 7, 2015 A new analysis indicates that certain characteristics may increase a breast cancer survivor's risk of developing leukemia after undergoing chemotherapy and/or radiation. The findings are a first ... read more Early Gene Therapy Results in Wiskott-Aldrich Syndrome Promising Dec. 6, 2015 Researchers reported promising preliminary outcomes for the first four children enrolled in a US gene therapy trial for Wiskott-Aldrich syndrome (WAS), a life-threatening genetic blood and immune ... read more Gene Therapy Restores Immunity in Children and Young Adults With Rare Immunodeficiency Dec. 6, 2015 Gene therapy can safely rebuild the immune systems of older children and young adults with X-linked severe combined immunodeficiency (SCID-X1), a rare inherited disorder that primarily affects males, ... read more MECP2 Duplication Syndrome Is Reversible, Study Suggests Nov. 25, 2015 The MECP2 Duplication Syndrome is reversible, say researchers. Importantly their study paves the way for treating duplication patients with an antisense oligonucleotide ... read more Gene Therapy: Promising Candidate for Cystic Fibrosis Treatment Nov. 16, 2015 An improved gene therapy treatment can cure mice with cystic fibrosis (CF). Cell cultures from CF patients, too, respond well to the treatment, suggest new encouraging ... read more Link Found Between Genetic Mutations, Proliferation, Immune Surveillance in Lung Cancer Nov. 11, 2015 There are four gene mutations (KRAS, TP53, STK11, and EGFR) that most commonly occur in lung cancer; however, there are limited effective therapies to target these mutations. With this in mind, ... read more Nov. 9, 2015 Genome editing techniques for blood stem cells just got better, thanks to a team of researchers. In a new article, they describe a new, more efficient way to edit genes in blood-forming or ... read more Nov. 2, 2015 Eye drops have been used to deliver the gene for a growth factor called granulocyte colony stimulating factor (G-CSF) in a mouse model of brain ischemia. The treatment led to a significant reduction ... read more Oct. 21, 2015 Delivering the hormone leptin directly to the brain through gene therapy aids weight loss without the significant side effect of bone loss, according to new ... read more New Study Explains Why You Bulk Up With Resistance Training, Not Endurance Training Oct. 20, 2015 Resistance and endurance exercises activate the same gene, PGC-1?, but the processes stimulated for the muscles to adapt depend on the exercise type. A new study offers insight into why the physical ... read more Researchers Identify Gene That Increases Risk of Sudden Death in Patients With Mild Epilepsy Oct. 15, 2015 A gene mutation that increases the risk of sudden unexpected death in epilepsy (SUDEP) in patients with mild forms of the disease has been discovered by a group of ... read more Oct. 8, 2015 Compared with direct gene injection, cell-mediated GDNF gene delivery led to considerably more pronounced preservation of myelinated fibers in the remote segments of the spinal cord (5 vs 3 mm from ... read more 'Alarm Clock' of a Leukemia-Causing Oncogene Identified Oct. 8, 2015 Mutations in DNMT3A gene cause MEIS1 activacion, triggering leukemia, a research team ... read more Oct. 5, 2015 A novel mouse model for the vision disorder Leber hereditary optic neuropathy (LHON) has been developed by researchers who have found that they can use gene therapy to improve visual function in the ... read more Genetic Polymorphism Associated With Lung Cancer Progression Oct. 5, 2015 Genetic polymorphisms associated with cancer progression lead to variations in gene expression and may serve as prognostic markers for lung cancer, researchers show. They found that in patients with ... read more New Hope for Lou: Unexplored Therapeutic Targets for ALS Sep. 3, 2015 No cures exist for amyotrophic lateral sclerosis (ALS), and the only approved therapy slows the progression by only a few months. A new study identifies a promising unexplored avenue of treatment for ... read more

Thursday, January 28, 2016

Saturday, December 12, 2015

Tuesday, December 8, 2015

Monday, December 7, 2015

Sunday, December 6, 2015

Wednesday, November 25, 2015

Monday, November 16, 2015

Wednesday, November 11, 2015

Monday, November 9, 2015

Monday, November 2, 2015

Wednesday, October 21, 2015

Tuesday, October 20, 2015

Thursday, October 15, 2015

Thursday, October 8, 2015

Monday, October 5, 2015

Thursday, September 3, 2015

Tuesday, September 1, 2015

Wednesday, August 12, 2015

Friday, August 7, 2015

Thursday, July 30, 2015

Monday, July 20, 2015

Saturday, July 11, 2015

Friday, July 10, 2015

Thursday, July 9, 2015

Friday, July 3, 2015

Thursday, June 25, 2015

Friday, June 19, 2015

Monday, June 15, 2015

Friday, June 12, 2015

Thursday, June 11, 2015

Wednesday, June 10, 2015

Sunday, May 31, 2015

Tuesday, May 26, 2015

Thursday, May 14, 2015

Wednesday, May 13, 2015

Monday, May 11, 2015

Tuesday, May 5, 2015

Monday, May 4, 2015

Sunday, May 3, 2015

Wednesday, April 29, 2015

Monday, April 27, 2015

Wednesday, April 22, 2015

Tuesday, April 21, 2015

Friday, April 17, 2015

Thursday, April 16, 2015

Monday, April 13, 2015

Wednesday, April 8, 2015

Monday, April 6, 2015

Friday, April 3, 2015

Wednesday, March 25, 2015

Monday, March 23, 2015

Monday, March 16, 2015

Thursday, March 12, 2015

Thursday, March 5, 2015

Monday, March 2, 2015

Monday, February 23, 2015

Wednesday, February 18, 2015

Wednesday, February 4, 2015

Tuesday, February 3, 2015

Thursday, January 29, 2015

Tuesday, January 20, 2015

Monday, December 15, 2014

Monday, December 8, 2014

Thursday, December 4, 2014

Tuesday, November 25, 2014

Thursday, November 20, 2014

Tuesday, November 18, 2014

Wednesday, November 12, 2014

Wednesday, October 29, 2014

Wednesday, October 8, 2014

Thursday, October 2, 2014

Thursday, September 25, 2014

Wednesday, September 17, 2014

Tuesday, September 9, 2014

Tuesday, September 2, 2014

Friday, August 29, 2014

Thursday, August 28, 2014

Monday, August 25, 2014

Wednesday, August 20, 2014

Monday, August 11, 2014

Sunday, August 10, 2014

Tuesday, August 5, 2014

Friday, July 11, 2014

Thursday, July 10, 2014

Sunday, June 29, 2014

Thursday, June 26, 2014

Originally posted here:
Gene Therapy News -- ScienceDaily

Read More...

High-fat diets may spur cancer by activating tumor-prone …

August 4th, 2016 9:41 am

Chowing down on a high-fat diet may not only grow your waistline. It may also plump stem cell populations in your gutcells that are prone to producing tumors.

After about a year of feeding mice a diet of 60 percent fat, researchers found that the rodents had an unusually hefty population of cancer-susceptible intestinal stem cells and cells that act like stem cells. Those cells were supercharged by a protein called PPAR-, which can be switched on by the presence of fatty acids in the gut, the researchers reported.

The findings, published in Nature, may explain why epidemiological data in humans has repeatedly linked obesity to boosted risks of cancer, particularly colon cancer. It may also offer researchers a new target for knocking back the risks of cancer in the obese.

In the gut, there is usually a tiny pocket of stem cells that works to replenish the cells that line the intestine. These cells hang around for a lifetime, giving them extra opportunities to acquire mutations that could spur tumors.

In the fat-fed mice, which grew chubby, this tiny stem cell population unexpectedly flourished. And, progenitor cellsspecialized progeny of stem cellsstarted acting more like their parents, too. They lived longer, upping their opportunities to acquire mutations and tumor-spawning potential.

The researchers found that PPAR- was behind that boom in stem and progenitor cells. In petri-dish experiments, the researchers found that fatty acids from the high-fat diet increased the amounts of PPAR- cells were making.

That makes sense because the protein is known to switch on metabolic machinery that helps burn fat over carbohydrates. But the protein also seems to spark specific genetic changes that ignite the two cell populations, the researchers suggest.

In their fat mice, the researchers noted higher rates of spontaneous tumors than in control mice.

Still, the researchers will need to do more work to know if PPAR- and the stem cells explain the link between cancer and obesity in humans.

Nature, 2015. DOI: 10.1038/nature.2016.19484 (About DOIs).

See the original post:
High-fat diets may spur cancer by activating tumor-prone ...

Read More...

Sports Medicine | Stanford Health Care – ValleyCare …

August 4th, 2016 9:41 am

ValleyCare offers comprehensive sports medicine care at the award-winning, state-of-the-art LifeStyleRx in Livermore and at ValleyCare Medical Center in Dublin.

Patients have access to a multidisciplinary team of sports medicine physicians, orthopedic surgeons, physical therapists, certified athletic trainers and strength and conditioning specialists.

We work to return athletes to their sport as quickly and safely as possible, through aggressive and innovative treatment and rehabilitation.

A concussion may be caused by a bump, blow or severe rapid movement of the head that can change the normal function of the brain. Every head injury is serious. Common terms that people use to describe a head injury are ding and bell ringer.

In January 2012, California passed a law that requires high school athletes to be taken out of sports following any head injury and receive written clearance by a physician prior to returning to play.

ImPACT testing is a computerized neurocognitive test that gives clinicians the ability to return an athlete to safe sports participation following a head injury. The test may also be used as a tool to gather baseline information, which provides normal results for comparison when a head injury does occur. The test includes memory skills, concentration and questions that require the individual to problem solve.

Here at ValleyCare Physical and Sports Medicine, we can provide sports teams with the baseline testing. The testing is administered by a Certified Athletic Trainer in one of our computer labs. The results are reviewed by a physician, as well as stored in the National Data Base. Testing should be administered prior to the beginning of the sports season. Scheduling is open Monday through Friday, between 9am and 7pm.

Being proactive and keeping our youth safe is our goal. Let it be yours too. To find out more information about ImPACT testing at ValleyCare, please call Kimberly Connors, ATC at 925.373.4019.

Located within the state-of-the-art LifeStyleRx facility, sports-specific physical therapy by licensed therapists with extensive experience in the prevention and treatment of sports-related injuries is available.

Our program especially caters to pediatric and adolescent athletes who require a special level of care and attention due to various age-related concerns. Through experience and education in Pilates, plyometrics and sports-specific training, we can provide an accelerated rehabilitation program when appropriate. Access to the latest equipment at LifeStyleRx allows us to provide strength and endurance training as well. Regular contact with the athletic trainers at the local schools gives us the ability to quickly modify individual programs for a faster and safer return to the sport.

Our goal is to return the athlete to sport as quickly as possible and help avoid future injuries. An individual program will be designed for each athlete that most likely will include instruction in a home or gym program for strength and flexibility, as well as education about the injury and the biomechanics of movement in order to help avoid future injury.

Physician referral is required. Most insurance plans will cover physical and sports medicine services. ValleyCare accepts all PPOs, some HMOs and Medicare.

Go here to see the original:
Sports Medicine | Stanford Health Care - ValleyCare ...

Read More...

Spray on some stem cells and grow your own skin! | Katie PhD

August 4th, 2016 9:41 am

Ok. Bits of this film are a little grim, but its worth it. Well, go on then!

Amazing right? And yes, its real! I have to admit I double-checked the date when my friend forwarded me the National Geographic link, but April first it was not. Researchers at the University of Pittsburgs McGowan Institute for Regenerative Medicine have made the skin cell spray gun a very real, very effective treatment for burn victims.

So how does it work? At its core, this treatment relies on the unique properties of stem cells, so thats where Ill begin. Stem cells

Stem cells have fascinated biologists for years. They are unique amongst all other cells of the body in two ways; their capacity for self-renewal, and their ability to give rise to many different cell types.

Embryonic stem cells, which frequently (and controversially) make the news, are derived from a developing fetus. They are the ultimate in stem cell-iness because they have the potential to direct the development of an entire organism. This means that they contain all the information need to make muscles, nerves, eyes etc. And naturally this pluripotency (from the Latin pluri meaning many, and potency or potential) seemed like a fantastic quality for biologist to understand. Not only were there fundamental developmental principles to be learned, the medical applications were endless. However, glaring ethical issues arose regarding the taking of a life to save a life (that I wont get into here) that have resulted in the stringent regulation of embryonic stem cell research.

And so researchers turned to adult stem cells. While adult stem cells are not as versatile as embryonic stem cells, they do have the potential to direct the development of certain cell lineages. For example hematopoietic stem cells, which reside in your bone marrow, can divide asymmetrically into all the different cells of your blood. Similarly, all the different layers of your skin have ancestral skin stem cells.

Research into embryonic stem cells resulted in the identification of certain genes that were expressed in, and required by, stem cells. In 2006, a Japanese group generated the first induced pluripotent stem cells. Since then much work has gone into understanding the potential of these induced stem cells. However due to genetic manipulation and lack of correct genomic imprinting (small chemical modifications in our DNA that are laid down in the egg), induced pluripotent stem cells have the unfortunate ability to become cancerous. As detailed in a recent paper in Cell however, while these cells are not yet ready for the clinic, this should not prevent them from being used in a laboratory setting. Stem cells as a treatment

Bone marrow transplantation was the first example of a stem cell therapy. In 1959 the French surgeon Georges Math treated six nuclear power plant workers who had been so severely irradiated that their hematopoietic stem cell populations had been destroyed. The procedure has since been used with great success in the treatment of leukemia.

As with all transplants, the potential of the host rejecting the donor tissue exists. This rejection occurs because of subtle cellular differences between each and every one of us. Our immune system recognizes these differences as foreign, much as it would any other pathogenic invader, and mounts a formidable defense. With the development of tissue typing procedures and administration of immunosuppressive drugs, transplant rejection has significantly decreased.

By far the best way of avoiding rejection, however, is to transplant the recipients own tissue. In certain procedures, such as small areas of skin grafting, such auto-grafting is a viable option. But in others, such as in the case of organ transplantation, it is not. And this is where stem cells can sweep in and save the day.

Tissues in dishes

We have long had the capacity to grow cells in vitro (which literally means within a glass). Bacterial cells grow happily in test tubes when provided with simple nutrients and an incubator, as do yeast cells. Mammalian cells are a little more difficult to deal with, but again we have been culturing them in the lab for over a hundred years. All they require is a container to grow in that protects them from infection, liquid media containing essential amino acids and other nutrients, and a warm humid chamber in which to grow.

I am however talking about growing one type of cell at a time. Growing an organized tissue presents a far greater challenge. Not only do the cells have to grow and divide, they have to interact with one another and take on specialized roles within the tissue. Normally in our bodies external forces and small molecules send signals between cells that direct this process. Culturing a tissue in vitro requires a significant understanding of how the tissue forms, and an ability to isolate the stem cells from which the tissue is derived.

In the case of transplantation, the stem cells can be derived from the patient who will receive the cultured tissue, thus removing the chance of complications arising due to donor incompatibility. As you saw in the video, skin grafts have been performed in this way for quite some time, but with variable success.

The skin gun

And this is of course where the genius of the skin gun, and its inventor Joerg C. Gerlach, comes in; it bypasses the need for the in vitro tissue culturing. Skin stem cells that had been destroyed in the burn are replaced, and then the tissue is allowed to heal. As in the case of tissue culture in a lab, these cells require a sterile and nutrient rich environment to thrive. After the initial spraying, the wound is covered with a dressing that contains a synthetic circulatory system that brings nutrients to the infant skin and removes any toxins and waste products.

The speed and effectiveness of this treatment is out of this world. The guy in the video didnt even have a scar after his treatment. Perhaps the spray gun as a means of stem cell delivery is unique to skin regeneration, but there are a couple of features that should be transferable to other transplants, particularly the ability to enrich a patients own stem cells and re-apply them to damaged tissue. This will likely be advanced from burgeoning knowledge on where adult stem cells reside in our body, in so-called stem cell niches. With skin stem cell therapy now a reality, what will be next? Will we be able to re-grow more complex organs such as kidneys? Or will we be able to harvest healthy stem cells from a niche before a disease such as leukemia becomes debilitating? What do you think?

Bock, C., Kiskinis, E., Verstappen, G., Gu, H., Boulting, G., Smith, Z., Ziller, M., Croft, G., Amoroso, M., & Oakley, D. (2011). Reference Maps of Human ES and iPS Cell Variation Enable High-Throughput Characterization of Pluripotent Cell Lines Cell, 144 (3), 439-452 DOI: 10.1016/j.cell.2010.12.032

Hi Peter,

Thanks for the links. I should probably have pointed out in my article that this idea is not totally novel. The Australian plastic surgeon Dr. Fiona Wood has been using a similar technique for close to a decade. She has since started a company, http://www.avitamedical.com/index.php?ob=1&id=37. The technique was used extensively to treat burn victims of the Bali bombings in 2002. The recent development of the stem cell gun has basically increased the efficiency of the system, reduced damage caused to the stem cells during spraying, and made the technique more user friendly in a hospital setting.

However, I searched and searched and there is no Nature paper, which honestly baffled me too.

I was happy to see in that link that a clinical trial is in the works. Hopefully from that some concrete data can be collected as to the precise efficacy of the cell spray system, as well as a peer-reviewed article on the subject. It seems to me that burn experts are divided on the merit or value of the treatment. In my opinion the only way a consensus can be reached is through a thorough, scientific and transparent trial. But should the therapy prove itself in that setting, I think it is a fantastic advancement in the therapeutic use of adult stem cells.

Would this work on a aged skin, skin damaged other than fire, frostbite, gangrene, cancer, etc?

What about those sunbathers with leathery type of skin?

Thanks

Ha I like your idea about the leathery sun-worshipers! I think stem cell therapy like this has potential for aiding wound healing, ie where large amounts of skin have had to be removed. But I do not think it could help adult skin thats already present. Youd have to remove the whole leathery mess and start againa new era of cosmetic surgery?

View post:
Spray on some stem cells and grow your own skin! | Katie PhD

Read More...

Sports Medicine – Southeast Georgia Health System

August 4th, 2016 9:41 am

At Southeast Georgia Health System, we are dedicated to providing our area athletes with the best care possible through our Sports Medicine Program aimed at preventing, recognizing and managing athletic injuries.

Our certified athletic trainers provide services for three area high schools in Glynn Country. These services include practices, athletic events and daily athletic training room hours during the school year. Each trainer is experienced in concussion recognition and management as well as ImPACT concussion testing for high-risk sports.

Our certified athletic trainers are skilled and experienced in the prevention of athletic injuries and the management of athletes' health and well-being. They also assist in the rehabilitation of injured athletes and work with players both on and off the field. Our Certified athletic trainers work under the supervision of Beau Sasser, M.D., director of the Sports Medicine Program.

In addition to our area schools, we offer our expertise to local youth and community sports organizations. Services include:

Go here to see the original:
Sports Medicine - Southeast Georgia Health System

Read More...

Home | Oppenheimer Endocrinology

August 4th, 2016 9:41 am

Whether you suffer from diabetes, thyroid issues or other hormone-related problems, Oppenheimer Endocrinology of Sioux Falls is dedicated to treating you with advanced technology, 24/7 on-call service and the highest level of patient care possible. Dr. Mark Oppenheimer offers thirty years of medical expertise and a comfortable, friendly patient experience.

Oppenheimer Endocrinology is proud to offer a spacious clinic featuring immediate appointment availability, a convienent location and parking right outside the front door. You will find two registered nurses on staff, both certified in glucose monitoring equipment and the latest pump technology. Our entire staff is dedicated to the field of endocrinology. We take a personal approach to patient care and give our patients plenty of TLC. Because Dr. Oppenheimer is also an Internist, he is capable of identifying health problems outside the field of endocrinology.

Endocrinology allows Dr. Oppenheimer to work long-term with patients while helping them manage hormone-related disorders. He enjoys building relationships and helping patients achieve their goals. He also enjoys the flexibility his practice provides, such as helping people with diabetes adjust insulin doses over the phone and personally performing ultrasound diagnostics. He strives to offer cost-effective solutions and to always give patients more than they expect.

Phone: (605) 275-6525 Fax: (605) 275-6970

Here is the original post:
Home | Oppenheimer Endocrinology

Read More...

Section of Endocrinology – OUHSC

August 4th, 2016 9:40 am

Welcome to the website of the Section of Diabetes and Endocrinology at the University of Oklahoma Health Sciences Center. This site will introduce you to our doctors, researchers, and staff, and summarizes our clinical, educational, research, and diabetes prevention programs. Our Section is a core component of the Harold Hamm Diabetes Center at The University of Oklahoma.

Our clinical work encompasses the full spectrum of Diabetes and Endocrinology, including thyroid, adrenal, pituitary, bone, gonadal, and metabolic disorders. Outpatients are seen by physician referral, and have the opportunity to participate in clinical trials. Diabetes services are undergoing rapid expansion in collaboration with many other disciplines and partners on and off campus. Our goal is a state-wide effort to improve the lives of all people affected by diabetes and other endocrine disorders.

Our professional educational programs are aimed not only at medical students, residents, and fellows, but also at the broad spectrum of health care providers in hospitals and in the community who must work as a team to provide first class clinical care. We also place a major emphasis on education of communities, patients, their families, the general public, and makers of policies that affects community health.

Our clinical fellowship program, with six RRC-approved positions, seeks academically-oriented physicians for 2-, 3- and 4-year training programs. There are opportunities for experience of clinical and basic science research during the fellowship.

Our research program is a cornerstone of the Section. Its major emphasis is on diabetes and its vascular complications (eye disease, kidney disease, neuropathy, and accelerated atherosclerosis (hardening of the arteries)). We conduct clinical and basic science research with strong emphases on collaborations between clinicians and basic scientists, on linking different disciplines that are relevant to diabetes, on building partnerships with communities, particularly minority communities that are severely afflicted by diabetes, and on involving trainees in research. Our program has brought more than 40 new extra-mural grants and many new investigators to our Section in the past four years. Two major, five year NIH program grants were awarded in late 2007: a Diabetes Center of Biologic Research Excellence, and in collaboration with the OU College of Public Health, an Oklahoma Center on American Indian Diabetes Health Disparities. In 2012 the CoBRE "Diabetes Center of Biologic Research Excellence" was awarded a five year renewal under the leadership of Dr. Jian-Xing Ma.

Go here to read the rest:
Section of Endocrinology - OUHSC

Read More...

Metabolism, Diabetes & Endocrinology – Temple University …

August 4th, 2016 9:40 am

The Section is widely known for its diabetes research and treatment. It also serves as a resource for the study and management of hypoglycemia. Special endocrinology services include needle aspiration of thyriod nodules; diagnosis and management of pituitary tumors; and diagnosis and treatment of hypothyroidism, hypertension and general endocrine disorders.

1316 W. Ontario Street Jones Hall, First Floor (215) 707-4600

E. Victor Adlin, MD Specialty interests: hypertension, osteoporosis, thyroid and adrenal disease

Jonathan Anolik, MD Specialty interests: Clinical endocrinology, diabetes, metabolic diseases

Kristin Criner, MD Specialty interests: diabetes, obesity, thyroid cancer

Ajaykumar Rao, MD Specialty interests: hypertension, diabetes, endocrinopathies in the ICU

Daniel Rubin, MD Specialty interests: diabetes

Elias Siraj, MD Specialty interests: diabetes mellitus, diabetes after transplantation, thyroid disorders, general endocrinology

Imali Sirisena, MD Specialty Interests: Diabetes and obesity management and prevention with both lifestyle and medical therapies; thyroid disorders involving hypothyroidism, thyroid nodules, and thyroid cancer; metabolic bone disorders

Cherie L. Vaz, MD Specialty interests: aging related diseases in endocrinology, oxidative stress from high fat meals, antioxidant agents and therapeutic role in diabetes and metabolic syndrome

Kevin Jon Williams, MD Section Chief Specialty interests: lipid and lipoprotein abnormalities, diabetes

Read more from the original source:
Metabolism, Diabetes & Endocrinology - Temple University ...

Read More...

Sports Medicine – Youngstown State

August 4th, 2016 9:40 am

YSU student-athletes have two impressive sports medicine centers at their disposal to treat and prevent injuries.

The Willard Webster Sports Medicine Center inside of Stambaugh Stadium is the main hub and serves the majority of YSU's athletic teams. There is also a training and rehabilitation room in Beeghly Center that caters to the needs of the volleyball, swimming and diving and men's and women's basketball squads. The centers are well-equipped to handle any needs with the latest available and innovative equipment for the care and prevention of injuries.

John Doneyko has served as the Head Athletic Trainer since 2008 after serving in the department for 25 years. A licensed athletic trainer in Ohio and a nationally-certified Athletic Trainer, Doneyko is assisted by Jenna Lesko, Jeff Wills, Todd Burkey, Sarah Sydor and Martha Dettl. Also, numerous student assistants are on hand throughout the year and work closely with all teams attending games (home and away) and practices.

The Penguins staff is assisted by a host of health care professionals in the Youngstown area, providing state-of-the-art care in prevention and treatment of athletic injuries. Dr. Ray Duffett, Dr. James Shina and Dr. J.J. Stefancin are on hand for all home football and basketball contests and work with all sports throughout the year.

Willard Webster Sports Medicine Center

The football program and all other athletic teams are served by the Willard Webster Sports Medicine Center on the first level of Stambaugh Stadium. The Center is well equipped to handle any needs with the latest available and innovative equipment for the care and prevention of injuries. Assisting Doneyko in the training room are Assistant Athletic Trainers Jenna Lesko, Jeff Wills, Todd Burkey, Sarah Sydor and Martha Dettl. Also, numerous student assistants are on hand throughout the year and work closely with all YSU athletic teams attending games (home and away) and practices.

The Penguins' staff is assisted by a host of healthcare professionals in the Youngstown area, providing state-of-the-art care in prevention and treatment of athletic injuries. Dr. Ray Duffett, Dr. James Shina and Dr. J.J. Stefancin are the team's physicians and are on hand on gamedays for home football and basketball games.

With the support of YSU's sports medicine staff, the communities physicians and their facilities, student-athletes can compete with the confidence that they are afforded the best care possible.

Phone Number: (330) 941-3190 Located in Room 1103 of Stambaugh Stadium (near the Jermaine Hopkins Academic Center)

From August through March, the Beeghly Center Athletic Training & Rehabilitation Room caters to the needs of volleyball, track and field, swimming & diving, and men's and women's basketball student-athletes.

Located on the lower level of the building, the Training Room is used throughout the volleyball, basketball and swimming and diving campaigns. The Center is well equipped to handle any needs with the latest available and innovative equipment for the care and prevention of injuries. Rehabilitation equipment along with training tables and the latest in sports medicine innovations are available to the student athlete.

Phone Number: (330) 941-3726 Located in Room 108 of Beeghly Center (lower level next to men's basketball locker room)

Read the original:
Sports Medicine - Youngstown State

Read More...

What is a Sports Medicine Physician? – AMSSM

August 4th, 2016 9:40 am

%PDF-1.3 % 32 0 obj << /Linearized 1 /O 34 /H [ 1221 313 ] /L 728856 /E 552874 /N 2 /T 728098 >> endobj xref 32 38 0000000016 00000 n 0000001107 00000 n 0000001534 00000 n 0000001845 00000 n 0000002157 00000 n 0000002468 00000 n 0000002787 00000 n 0000004033 00000 n 0000005271 00000 n 0000006512 00000 n 0000006569 00000 n 0000006590 00000 n 0000006831 00000 n 0000006851 00000 n 0000007035 00000 n 0000007057 00000 n 0000009211 00000 n 0000009232 00000 n 0000009464 00000 n 0000009484 00000 n 0000009601 00000 n 0000009722 00000 n 0000011167 00000 n 0000011189 00000 n 0000011246 00000 n 0000014763 00000 n 0000014785 00000 n 0000017773 00000 n 0000026768 00000 n 0000026790 00000 n 0000026812 00000 n 0000026836 00000 n 0000518283 00000 n 0000518304 00000 n 0000519360 00000 n 0000519383 00000 n 0000001221 00000 n 0000001513 00000 n trailer << /Size 70 /Info 28 0 R /Root 33 0 R /Prev 728088 /ID[<2f13c81ee21d198822aba294fb72bf8c><2f13c81ee21d198822aba294fb72bf8c>] >> startxref 0 %%EOF 33 0 obj << /Pages 29 0 R /Type /Catalog /DefaultGray 30 0 R /DefaultRGB 31 0 R /Outlines 27 0 R >> endobj 68 0 obj << /S 100 /O 230 /Filter /FlateDecode /Length 69 0 R >> stream Hb``b``9Ti @16OZ I2ta hrc[3g6@@)X``ei% TX&0Ll9AMAA($pcla0j!,<< /Type /Page /Parent 29 0 R /Resources << /Font << /F1 38 0 R /F2 39 0 R /F3 40 0 R /F4 52 0 R >> /XObject << /I1 63 0 R /I2 53 0 R /I3 67 0 R /I10 67 0 R >> /ProcSet 55 0 R >> /Contents 41 0 R /CropBox [ 118.51758 92.55962 672.21689 520.334 ] /MediaBox [ 0 0 792 612 ] /Rotate 0 >> endobj 35 0 obj << /Type /FontDescriptor /FontName /NCELNI+AGaramond-Regular /Flags 1048626 /FontBBox [ -183 -269 1099 851 ] /MissingWidth 250 /StemV 74 /StemH 74 /ItalicAngle 0 /CapHeight 660 /XHeight 394 /Ascent 720 /Descent -270 /Leading 83 /MaxWidth 1212 /AvgWidth 469 /FontFile3 59 0 R >> endobj 36 0 obj << /Type /FontDescriptor /FontName /MCELNI+AGaramond-Bold /Flags 1048626 /FontBBox [ -158 -269 1147 862 ] /MissingWidth 260 /StemV 130 /StemH 130 /ItalicAngle 0 /CapHeight 660 /XHeight 400 /Ascent 720 /Descent -270 /Leading 83 /MaxWidth 1196 /AvgWidth 485 /FontFile3 58 0 R >> endobj 37 0 obj << /Type /FontDescriptor /FontName /KCELNI+Helvetica-Condensed-Bold /Flags 1048624 /FontBBox [ -174 -224 1071 990 ] /MissingWidth 250 /StemV 79 /StemH 79 /ItalicAngle 0 /CapHeight 556 /XHeight 375 /Ascent 750 /Descent -189 /Leading 83 /MaxWidth 1111 /AvgWidth 447 /FontFile3 56 0 R >> endobj 38 0 obj << /Type /Font /Subtype /Type1 /Name /F1 /BaseFont /KCELNI+Helvetica-Condensed-Bold /FirstChar 0 /LastChar 255 /Widths [ 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 333 250 500 500 833 667 250 333 333 500 500 250 333 250 278 500 500 500 500 500 500 500 500 500 500 250 250 500 500 500 500 800 556 556 556 611 500 444 611 611 278 444 556 500 778 611 611 556 611 611 556 500 611 556 833 556 556 500 333 250 333 500 500 333 444 500 444 500 444 278 500 500 222 222 444 222 778 500 500 500 500 333 444 278 500 444 667 444 444 389 274 250 274 500 250 556 556 556 500 611 611 611 444 444 444 444 444 444 444 444 444 444 444 222 222 222 222 500 500 500 500 500 500 500 500 500 500 500 400 500 500 500 333 440 500 800 800 750 333 333 549 833 611 713 500 549 549 500 500 494 713 823 549 274 300 300 768 667 500 500 333 500 549 500 549 612 500 500 1000 250 556 556 611 833 722 500 1000 389 389 222 222 500 494 444 556 167 500 278 278 500 500 500 250 222 389 1111 556 500 556 500 500 278 278 278 278 611 611 790 611 611 611 611 222 333 333 333 333 250 250 333 333 333 333 ] /Encoding /MacRomanEncoding /FontDescriptor 37 0 R >> endobj 39 0 obj << /Type /Font /Subtype /Type1 /Name /F2 /BaseFont /MCELNI+AGaramond-Bold /FirstChar 0 /LastChar 255 /Widths [ 260 260 260 260 260 260 260 260 260 260 260 260 260 260 260 260 260 260 260 260 260 260 260 260 260 260 260 260 260 260 260 260 260 254 472 520 520 866 825 253 340 340 405 520 260 328 260 339 520 520 520 520 520 520 520 520 520 520 260 260 520 520 520 332 769 624 635 689 793 593 548 734 806 371 383 715 585 908 748 788 601 788 664 506 645 740 642 960 665 575 614 340 321 340 520 500 380 443 532 416 537 420 311 479 547 286 281 532 278 806 550 516 543 528 371 358 323 544 457 682 458 469 415 340 248 340 520 260 624 624 689 593 748 788 740 443 443 443 443 443 443 416 420 420 420 420 286 286 286 286 550 516 516 516 516 516 544 544 544 544 490 374 520 520 525 395 490 573 780 780 1070 380 380 549 841 788 713 520 549 549 520 536 494 713 823 549 274 374 404 768 627 516 332 254 520 549 520 549 612 432 432 1000 260 624 624 788 1018 740 500 1000 472 472 253 253 520 494 469 575 100 520 255 255 566 566 492 260 253 472 1188 624 593 624 593 593 371 371 371 371 788 788 790 788 740 740 740 286 380 380 380 380 380 380 380 380 380 380 ] /Encoding /MacRomanEncoding /FontDescriptor 36 0 R >> endobj 40 0 obj << /Type /Font /Subtype /Type1 /Name /F3 /BaseFont /NCELNI+AGaramond-Regular /FirstChar 0 /LastChar 255 /Widths [ 255 255 255 255 255 255 255 255 255 255 255 255 255 255 255 255 255 255 255 255 255 255 255 255 255 255 255 255 255 255 255 255 250 220 404 500 500 844 818 235 320 320 394 500 250 320 250 327 500 500 500 500 500 500 500 500 500 500 250 250 500 500 500 321 765 623 605 696 780 584 538 747 806 338 345 675 553 912 783 795 549 795 645 489 660 746 676 960 643 574 641 320 309 320 500 500 360 404 500 400 509 396 290 446 515 257 253 482 247 787 525 486 507 497 332 323 307 512 432 660 432 438 377 320 239 320 500 255 623 623 696 584 783 795 746 404 404 404 404 404 404 401 396 396 396 396 257 257 257 257 525 486 486 486 486 486 512 512 512 512 480 348 500 500 506 388 500 523 790 790 1100 360 360 549 850 795 713 500 549 549 500 512 494 713 823 549 274 332 387 768 585 486 321 220 500 549 500 549 612 378 378 1000 250 623 623 795 1012 729 500 1000 404 404 235 235 500 494 438 574 100 500 233 233 522 522 480 250 215 384 1144 623 584 623 584 584 338 338 338 338 795 795 790 795 746 746 746 257 360 360 360 360 360 360 360 360 360 360 ] /Encoding /MacRomanEncoding /FontDescriptor 35 0 R >> endobj 41 0 obj [ 43 0 R 45 0 R 47 0 R 49 0 R 51 0 R ] endobj 42 0 obj 144 endobj 43 0 obj << /Length 42 0 R /Filter [ /ASCII85Decode /FlateDecode ] >> stream 8;T3_Ymgb#$j8)"%pQlaD:rQO:;SqT!U.W*5skJ(,G>Q9>)c!cQ2!Ta)^KaVZ8(<< :_k76Wf?a*2otM_q#rKgRMT";V'@dp"5uu!3p[4q5;>Z*%6F6%RJEYRPNtnIn$8Gm Vl+nC].b3,~> endstream endobj 44 0 obj 87 endobj 45 0 obj << /Length 44 0 R /Filter [ /ASCII85Decode /FlateDecode ] >> stream 8;RemYml4;$j=?PIYXQRYq90,4Ukt78<"/ql"UP0aX%fnKf6N.[endstream endobj 46 0 obj 2057 endobj 47 0 obj << /Length 46 0 R /Filter [ /ASCII85Decode /FlateDecode ] >> stream 8;WU5gN)%,&H)/_iC@f)&)-A,aapo)(1u`UXlP)PD?RW1^-HA-rM3;/,K,qYTO8+ EU/WS">@sS`LaCPrXOklc%,h&99+*]j1aP0J5[S-CdH8HZJ/-*uA@UYU"ulA1WWP =PlFFlVhMi8$;1Ir*iQK9b5j;UlEJp6Q98MRnG;XtIojkCk"^+9p_j]EPKWA^Nlu *0.=+]m>o>o_V8SZ?ls_r8qJlRG(>>i@3Ja?LYA_3 p_1;IQTP8O=[jCDCNG1+jkm!Z<>r->m4oM(iZdVKBb[-Zo@DG-A0>CLK#([rZ-ORmf)'=WE50au&&]b7Z("pleNA5@WmsnL,Kgmhrb_]U)<.Ll;NE 86n28N'Pqs=Z000+tYkmQE@]2g+eE;fDVpP7o7_Gb3IA`IWFBgij:)(E$h8r:Pua2 "sMtSIio'A/P@:>5"o)nO'C5P&n$FPgG&7a(_F`k/7B1C%M6IC(E85Q$E)R2+nB&TuL UsG:K._B<'F787^.>l^c1`VLE7HSlnLbHphmfONP'3FTBrHPLtMQC.OA6:FB7. B9Bos]=/lfQQhNr1nXPn.Q_c%K;@LpE>e:c_C*1aCe;m#D'NgL4@'$H.)PT#g/DFpn4 0]FrPfXpboWBXEYOW8,HnlggP0b$j]p+ea;bZkUD%NtO"]Gs7Ub%X!eJh3Jc)IY7 khtbuQ!^PL5!:f0V]I;oI085&fQ?jA 0WNutk24=pX?4o1Z.OQFGcCZDV)F)uFI]b0S41QL[(N+i"2bi5B<-GO,H_ i/M"H/rcN5`oK-W67#r0`$?"'h=WLCr-jOi)!u3&Iat4D+>]d'UL;^tiDA_`#p_ 0@4MECK:dVhUGKi`C.iD"Q@&U`6`bB*f5$$23*=n-A=h"rY`-U>"nGhYnX.j7a]Ds fT2fO&!QK/30OV>44H&jUV[<"K%ub%*`]+aj2G.b!1qA83.dDN8-dS8cY$8u]'dA& G5%.M.0a2$84Gqf9A4g1=b%*CA!Ra)LL"Ije:hVV,ie.GkSHD=C101#oc* ZEkM:i0LdI0[,n<,m=1mYa?"A6Yn49>6LM[,eS:V*p9^l)LDQV5:&cULcZI6pgW> 4-1^Y.SN0F&DUIfN;OY`9Qb`4QbRCR?.RcBWD4<)D5fJ0:X01>5:SE',rjSV?% mUuCEg$YV<8-6D]7+3fWG(CCFQ<*Oo"$Mf&GbZA@KJcXCiPc:YIn_I9Y7gbSB5#8p bmb?32u!fl(<+V.ph`tPAH-6Amnj)rT'60(!XHqKtI*=9dcaP/A&b$M8TA%]'Xp ,^4KDZa.S,r4L0Wm[:49TNg_Ij-XMN#uYO$T#>oJ8D<5 @Jou+?A(?YH%l@;&f?LZV2'U0c7hgR]>.N;":?MKn1FiUn.S^UtbhYAs&>_A9 RLJdOmBN<4*462]!R#N%-GiAKjmh!1pruCD:Zr=tn^0sQ@;GtQ!QVbJn8;psDsd84 _BS+Ddih/sUFHBic&at8Uq-<<7E7XO8!4Y+#Ft+=#U%T;%FPGfeU;L`[6-!XIZ!*m =o8@bV6PI~> endstream endobj 48 0 obj 135 endobj 49 0 obj << /Length 48 0 R /Filter [ /ASCII85Decode /FlateDecode ] >> stream 8;TKf]+KZl$j8(W%p+>/qal+E'1*lM@"8M"]DhliJ@T'?gRUSC8?d`(#T%2oj_P-0 K6"eHV%*

Read more from the original source:
What is a Sports Medicine Physician? - AMSSM

Read More...

Sports Medicine Doctor | School, Career and Salary Guide

August 4th, 2016 9:40 am

Education

Students interested in become a physician must first complete a bachelors degree with a pre-med concentration that provides them with a solid foundation in biology, general chemistry, organic chemistry and physics. Gaining admission into medical school can be competitive, so students must complete the aforementioned courses and obtain excellent grades to be considered a viable applicant to medical schools.

Beyond this coursework, students will also be required to perform well on the Medical College Admission Test (MCAT) in order to secure a spot in medical school. While those interested in sports medicine are usually sports aficionados themselves (and therefore may take part in organized sports), this is in no way a requirement for admission into medical school or sports medicine.

Most sports medicine doctors complete a Doctor of Medicine (MD) degree or a Doctor of Osteopathic Medicine (DO) degree. These programs both involve four years of academic coursework in biology, biochemistry, anatomy, pathology, psychology, physiology, medical ethics and pharmacology. Following the completion of medical school, students are awarded their respective degree (M.D. or D.O). Next, these newly minted physicians must go on to complete a clinical residency, which provides them with several years of hands-on practice in a variety of clinical settings under the supervision of fully trained, attending physicians (see below).

Three-year clinical residencies in internal medicine, family medicine, or emergency medicine (or a four-year residency in physical medicine and rehabilitation) all offer suitable training for an aspiring sports medicine physician. Other, more surgically inclined students may instead opt for a five-year residency in orthopedic surgery. During residency, it may be possible to secure an elective rotation in sports medicine to gain early exposure.

All states require medical doctors to be licensed, so sports medicine doctors must check with their states licensing board for specific requirements.

In addition to a license, doctors may seek certification by a recognized professional organization. This certification will help make the doctor a better job candidate since it will show that he or she has met the organizations professional requirements and is staying up-to-date in developments in this subspecialty through continuing education courses. Certification in sports medicine is offered by the following organizations:

Since sports medicine is a subspecialty, doctors must get a certification of added qualification (CAQ) in sports medicine. To prepare for this, doctors complete a two-year fellowship in sports medicine at a hospital, rehabilitation facility or university athletic department. These two years expose doctors to different types of athletic-related injuries and methods of diagnosing and treating them. Additionally, the fellowship provides experience with orthopedic surgeries, rehabilitative techniques, brain trauma, nutrition, and performance psychology. Orthopedic surgeons can also apply for fellowships in this field, but added qualification certification is not required.

As with all physicians, specialists and non-specialists alike, sports medicine physicians must possess and demonstrate empathy, compassion, strong interpersonal communication abilities, and proficient problem-solving skills in order to provide timely diagnosis and optimal clinical outcomes for their patients. In addition, sports medicine physicians must also possess good physical health, dexterity, and stamina if they intend to perform physical therapy-related treatments.

Sports medicine doctors may opt to base their practice in outpatient clinics, large hospitals, or academic medical institutions. Those in private practice can establish their own practices, or join current groups with the ultimate aim of becoming a partner. Alternatively, a position in larger hospitals will provide the sports doctor with opportunities for advancement, depending on experience and continuing education. For example, after several years of productive performance, staff physicians may take on supervisory or management roles, potentially becoming chairperson of a department.

If you would like to gain the necessary education to become a sports doctor, we highly recommend that you check out our free School Finder Tool located HERE.

Read more:
Sports Medicine Doctor | School, Career and Salary Guide

Read More...

The Sports Medicine Clinic: Advanced Manual Therapy & Sports …

August 4th, 2016 9:40 am

Sports Medicine

"Sports medicine" has become the general description for any medical and orthopaedic care of the physically active. However, we, the staff and physicians at The Sports Medicine Clinic, firmly believe that no one else in the Pacific Northwest understands and practices sports medicine as we have since 1963.

Besides specialty training, virtually all of our physicians have additional advanced sports medicine fellowship training. Our team includes primary care and sports medicine physicians, orthopedic and podiatric surgeons, physical therapists and a physiatrist.

As demonstration of our deep commitment to practice sports medicine in its truest spirit, our physicians at The Sports Medicine Clinic bring our expertise to the community and actively serve as team physicians and consultants for Seattle area's most accomplished sports teams, from high school to collegiate and professional levels. You will also see our physicians providing official medical coverage at many of the popular sports arenas and events across the Puget Sound region.

Regardless of the cause or the nature of your condition, The Sports Medicine Clinic brings that same level of commitment to help you overcome your injury and achieve your goals. We work with both youth and adult patients to:

Please give us a call if you have any questions about our sports medicine services or to schedule an appointment: (206) 368-6100.

View original post here:
The Sports Medicine Clinic: Advanced Manual Therapy & Sports ...

Read More...

Live Cell & Stem Cell Therapy – healing-arts.org

August 4th, 2016 9:40 am

Live Cell Therapy:

Live cell therapy was developed in Switzerland by Dr. Niehans. Over 2400 years ago, Hippocrates had theorized that, for example, if you had liver problems, the answer would be found in the healthy liver of a young animal because the livers of both man and animals operate almost exactly the same way. His theory applied to all organs and glands of the body: heart, lung, thymus, adrenals, spleen, etc.

Over the centuries, doctors and scientists scoffed at Hippocrates' theory. In the 1930s, Dr. Niehans reported success in curing a variety of illnesses with injections of live cell extracts from healthy animal organs mirroring the diseased organ in the human.

In the 1960's, however, separate radioactive labelling studies at the University of Vienna and the University of Heidelberg, showed unquestionably, that the vital constituents of a calf's gland or organ, when injected into a human, went directly to that same gland or organ. It appeared that the live cells offered unique biochemicals specifically needed by the diseased gland or organ which were unattainable elsewhere!

Dr. Niehans felt that the constituents of the gland or organ had to be extracted before the gland or organ began to deteriorate. He had his own cattle ranch next to his Clinique La Prairie in Switzerland, and butchered the calf the same day he planned to use its gland or organ. So, the gland or organ was still warm or "live" when he processed it. Unfortunately, extracting the important substances was excruciatingly slow. That's why the costs to go to the Clinique were so high.

[Return to "Quick-Index" for Live Cell & Stem Cell Therapy]

More about Dr. Paul Niehans:

The following is an excerpt from the book, Feeling Younger Longer, by Cornel Lumiere, 1973:

....In his Introduction to Cellular Therapy, Neihans devotes a brief section to "The Fate of the Cells After Injection." His opening sentence declares bluntly: "Nothing certain can be said on this subject, as the practitioners of this system of treatment are still of different opinions" (19, p.35).

He presented the varying theories in a series of questions:

1. When it is a question of cells needed by our organism, do the cells injected into the muscles remain alive and do they make their way towards the organ of which they bear the name if that organ is impaired? In other words, do the cells in question really make their way to the impaired organ? 2. Or do the injected cells continue to live in the muscles at the site of injection, the blood vessels assuring the supply of oxygen at the same time as the elimination of excretions? In other words, is it possible that the cells remain alive at the site of the injection and act on the impaired organ from a distance? 3. Or are the injected cells, attacked by antibodies, broken down into their elements, and are these elements utilized by the organism to rehabilitate the impaired organ? That is to say, disintegration of the injected cell, then utilization of the material by the organism for the purpose of reconstruction (19, pp. 35-36).

Niehans insist[ed] ... strongly [on] the use of ... whole cells rather than isolated components. He says: "Cells contain nuclei, chromosomes, granular tissue, mitochondria, protoplasm and many other materials. Many efforts have been made of late years to isolate these active substances and to inject them--a useless task--for the results obtained by using the cell itself as a unity (that is, according to the classical method of cellular therapy) are infinitely superior" (19, pp. 37-38).

While I was at the Clinique La Prairie, I asked Dr. Michel why cells were used in preference to hormones, since cells were frequently taken from glands such as the thyroid, hypothalamus, parathyroid, adrenals, and the sex glands. He replied to the effect that, although some excellent results have been achieved with hormones in a variety of complaints or deficiencies, in his experience and that of Professor Niehans, hormones are only a substitute, where cells actually cause a continuous regeneration by nature.

Niehans puts the case against hormones more strongly: "As the organism does not store hormones but produces only the quantities corresponding to the needs of the moment, treatment by hormones is only a temporary form of treatment and does not lead to a cure. This is precisely what happens with insulin. To that then is added in course of time an atrophy caused by inactivity of the gland, its cellular functions being totally exhausted.

"Hormonal therapy also has its limits. How, for example, can we treat a lesion of the [pituitary] with hormones when the cells of the [pituitary] act in part cyclically, in part according to the needs of the moment, and when the gland, according to our present knowledge, possesses 24 different hormone13s? (19, p.15).

Whole cells work better than isolated components and hormones. (19, p.112)

[Return to "Quick-Index" for Live Cell & Stem Cell Therapy]

Lyophilisate Whole Cells:

Treatment can be done with lyophilisate whole cells from Cytobiopharmica of Germany. Dr. Gerhard Heinstein, from Lohr, Germany, has twenty years experience in the use of whole, live cells with children and adults.

Some physicians have expressed concern about potential antibody/antigen reactions to whole cell therapy. To date, no adverse antigen and antibody reactions to the use of lyophilisates has been reported.

The Nobel Prize in Medicine and Physiology was awarded to Dr.'s Peter Medawar and Macfarlane Burnett in 1960, for their work in transplantation immunity. They showed that lyophilized tissue will not provoke an immune reaction. They also showed that fetal cells are less antigenic than any other types of cells. These studies were performed transfering allogenic spleen cell suspensions and leukocytes, which in the fresh state are highly immunogenic, from A-mice to CBA-mice.

When lyophilisized cells are implanted (injected), they are broken down by macrophages (tissue histiocytes). According to Dr.Trotsky of Israel, in 1985, the implantation of lyophilisized cells into 300 adults and children had only the production of local histamine at the site of injection in 10% of the population. This was an IgE mediated response. In his study, 5% had lethary and flu-like sypmtoms lasting 2-3 days, 5% with a slight rise in temperature for a couple hours to days, 30% with malaise lasting 10-15 days, 50% without any side effects, and 10% with Cell Therapy Local Reaction (CTLR) wherein, the histamine response took place. In an unpublished study, and personal communication with Dr. Harvey Good, a pediatrition in Scotland, he notes that in children the side effects are less, and approximately 75% of the children have no adverse response what so ever. If adults or children go through a general detoxification prior to cellular therapy, the incidence drops even further.

[Return to "Quick-Index" for Live Cell & Stem Cell Therapy]

Oral Organ Extracts:

In support of Hippocrates theory and Niehans therapy, Dr. W. Boecker directed a double-blind clinical trial on 146 patients with cirrhosis of the liver. Half were given a placebo, and half took a liver extract. Sixty-seven percent of those taking the liver extract had significant improvement in liver function (more than placebo).

In another double-blind study of 600 patients suffering from hepatitis, Dr. Kiyoshi Fujisawa at the Jikei Universtiy School of Medicine in Tokyo, showed that, in only 12 weeks, 35% of the patients taking a liver extract showed substantial improvement (better than placebo). He stated, "the results of this study clearly demonstrate that oral administration of liver hydrolysate preparations can be useful in the treatment of chronic hepatitis, and this efficacy is thought to derive from improved function of damaged hepatocytes and from subsidence of active changes of the liver.

Dr. Pietro Cazzola conducted a study of 130 patients with malfunctions of the immune system and reported that treating those patients with thymic gland extracts improved their conditions.

Dr. D.M. Kouttab of the Roger Williams Hospital and Brown University, reported health efficacy for extracts of the adrenal cortex.

Dr. Franco Pandolfi of the medical school at the University of Rome directed a double-blind clinical trial on elderly hospitalized patients. Half of the patients were given a thymic extract and half took a placebo. Those taking the extract had fewer infections over a six-month period than those receiving the placebo.

Dr. V. Cangemi followed 25 patients taking thymic extracts after cancer surgery and found that none of them got infections. Tests showed that their immune systems were substantially bolstered by the thymic extracts compared to controls.

Dr. Massimo Fedrico guided a double-blind clinical trial of 134 people undergoing chemotherapy. Half of the patients were given thymic extracts, and they lived 49% longer than those taking a placebo.

Dr. Alec Fiocchi led a double-blind clinical trial on patients with chronic respiratory infections. Half of the patients were given thymic extracts, and the other half received placebos. In only three months, but not during the winter cold season, those taking the thymic extracts had 30% fewer infections than the placebo group.

Tuftsin is a peptide found in spleen extracts. Dr. I. Florentin reported in the journal, Cancer Immunology, that laboratory animals given tuftsin showed a significant 3.1 fold increase of disease-fighting cells. Dr. M.S. Wleklik found that even the tiniest amount of tuftsin in vitro stimulated the production of TNF lymphokines. These lymphokines are killers of tumor cells. Dr. M. Bruley-Rosset gave elderly mice tuftsin for a few months, reporting in the Annals of the New York Academy of Sciences, that the capacity of disease-fighting macrophages in these old mice was restored to the level of much younger mice. Dr. M. Fridkin found that a deficiency of tuftsin is commonly found in people who get frequent infections as well as in cancer patients. AIDS patients also have very little tuftsin in their systems.

Calf heart extracts have 17 amino acids, five B vitamins, folic acid, calcium, iron, heparin, coenzyme Q10, cytochrome C and mesoglycan. A clinical study of the use of calf aorta in patients affected by chronic atherosclerotic arteriopathies showed a significant increase in femoral venous blood flow and an anticoagulant activity.

Folic acid is reported to reduce the oxidation of cholesterol Coenzyme Q10 assists the heart muscle in energy production. Cytochrome C helps all cells in the body convert oxygen and nutrients to energy.

The aorta is composed of a substance called mesoglycan, which provides structural support.

Dr. G. Laurora and researchers from the Cardiovascular Institute conducted double-blind trials on patients with early stages of arteriosclerosis (clogged arteries). Half of the patients received mesoglycan, and half took a placebo. A small section of one artery was scanned with high-resolution ultrasound before and after treatment. At the end of 18 months, the occlusion of the arteries of the patients taking the placebo had increased seven times more than those taking mesoglycan. Several clinical trials have shown that mesoglycan also deters blood clots and reduces the risk of strokes--even for people who have severely clogged arteries. Dr. F. Vecchio found that patients given mesoglycan for only 15 days experienced a 20% drop in "bad" cholesterol and 44% increase in "good" cholesterol.

A commercial product, Bioactive Cell Complex, is made from specific organ cells from young animals. The cells are "predigested" to liberate their ingredients. This matieral is freeze dried for maximum preservation. The orally ingested cells are organ-specific but not species-specific.

Theoretically, with autistic children, one would administer brain cells or gut cells for maximum efficacy.

[Return to "Quick-Index" for Live Cell & Stem Cell Therapy]

Stem Cell Therapy:

In principle, stem cells (immature cells that have not yet differentiated into specific types of cells) can be used to repair bone, cartilage, tendon and other injured or aged tissues. These cells can be derived from the patient's own bone marrow and thus present no problem of immune rejection.

Biologist at Osiris Therapeutics, in Baltimore, MD, have shown that human mesenchymal stem cells can be converted into bone cells, cartilage cells, fat cells and the stroma cells in the bone marrow that provide support for blood-forming cells.

Dr. Daniel R. Marshak, Osiris' chief scientific officer, said the mesenchymal stem cells could be formulated so that, when inserted in the right place in the body, they would change into the appropriate tissue.

Tests in animals show that when the cells are grown on ceramic and put into bone, they turn into bone-forming cells. If grown in a gel and inserted into cartilage, they metamorphose into cartilage cells. If injected into the bloodstream, the cells take up residence in the bone and turn into stroma cells.

A clinical trial is under way with breast cancer patients to explore the cells' stroma-forming abilities. Lack of stroma to support blood-forming cells may be why the bone marrow transplants given to cancer patients after chemotherapy are not always successful.

With Novartis AG, the Swiss pharmaceutical company, Osiris also plans to test in humans the cells' abilities to form new bone, tendon and cartilage.

The cells can also be converted to fat cells, which could prove useful in cosmetic surgery and possibly as material for breast implants.

Dr. Mark F. Pittenger,who identified the various factors needed to convert the cells into bone, cartilage, and fat, said he is now working to change them into heart-muscle cells. People are born with a fixed number of heart-muscle cells and the heart grows by enlargement of these cells, not by growing more. "We hope at the least we could prevent some of the scarring after a heart attack by implanting new cells," Pittenger said.

The human mesenchymal stem cells found in adult bone marrow are derived from the mesoderm, one of the three tissue types of the early embryo and the source of all the body's bone and connective tissue. The adult stem cells evidently retain much, and possibly all, of the mesoderm's magical plasticity.

[Return to "Quick-Index" of Live Cell & Stem Cell Therapy]

Research: "The Myelin Project":

The exciting work of researchers funded by The Myelin Project, whose goal is to remyelinate the human central nervous system, may someday have benefits for autistic children. Only time will tell if a specific area of damaged neurons can be found and potentially repaired with stem cells.

The first human trial, conducted by Dr. Timothy Vollmer at Yale University School of Medicine, will attempt to transplant myelin-forming Schwann cells into the brains of five patients with multiple sclerosis. The cells will be obtained from the sural nerves of the patients themselves. Although Schwann cells normally produce myelin in the peripheral nervous system, several recent experiments conducted on rodents and cats have shown these cells have the ability to remyelinate in the CNS as well.

While multiple sclerosis is a long way from autism, there is discussion of anti-myelin antibodies in autism, and there is talk of inflammatory processes involving myelin. Whether this technology can help autism if it works for multiple sclerosis is anybody's guess, but it's exciting to wonder about.

The Myelin Project funds a Cell Culture Unit at the University of Wisconsin-Madison, where Dr. Su-chun Zhang continues to generate cultures with ever-higher percentages of human oligodendrocyte precursors (OPs). Oligodendrocytes are the cells that normally myelinate the CNS. If obtainable in sufficient quantity, they would provide an alternative to Schwann cells for transplantation. The Unit has developed a method to track transplanted OPs by MRI, labeling the cells with iron particles. In another recent experiment, Dr. Baron-Van Evercooren and colleagues were able to remyelinate as many as 55% of the nerves in monkey spinal cord lesions by transplanting the monkeys' own Schwann cells. These initial positive results, however, have not been confirmed in subsequent attempts. She suspects that the viral labels she used to distinguish the transplanted cells caused them to die. She is trying again without viral labeling. If successful, this experiment would prove that CNS remyelination is feasible in higher animals.

Several researchers funded by The Myelin Project have injected myelin-forming cells into the ventricles of the brain of experimental animals and have shown that these cells were transported by the cerebrospinal fluid to all regions of the brain. This makes it more likely that injected cells will travel to where the myelin needs to be repopulated.

The Myelin Project has funded Dr. Oliver Brstle of the University of Bonn, Germany, and Dr. Evan Snyder of Harvard University to work with neural stem cells (NSC). These are self-renewing, multipotent cells, capable of differentiating into the major types of neural cells, including oligodendrocytes. One of their most potentially beneficial properties is their tendency to respond to signals in the CNS environment. In CNS diseases, these signals guide the cells to damaged areas. Second, they prompt them to differentiate into the specific cell type needed for the repair -- neurons in nerve diseases like Parkinson's and oligodendrocytes in myelin disorders like the leukodystrophies and multiple sclerosis.

NSCs are typically of fetal origin, but have also been found in the adult brain. NSCs can be multiplied in culture indefinitely as an "immortal" cell line. They could eventually provide an inexhaustible source of myelin-forming cells, eliminating the need for obtaining them from fresh tissue. Several research centers are now testing human NSCs to verify their safety and in particular to rule out any risk of their becoming cancerous. If this testing concludes favorably, then prospective myelin repair strategies could take a two-fold approach. NSCs would be injected into the ventricular system where the cerebrospinal fluid would circulate them to all parts of the CNS. Local signals would then come into play, guiding the cells to the specific demyelinated areas.

The Myelin Project has also funded Dr. Robin Franklin of the University of Cambridge to study olfactory ensheathing cells, a third type of myelin-producing cell. He has perfected a technique for demyelinating the area of rat brain connecting the cerebellum with the brain stem. He subsequently remyelinated the area by transplanting rat Schwann cells, which adds to the body of evidence in favor of Schwann cell transplantation as a way of repairing CNS myelin lesions.

The Myelin Project has also funded Dr. Inderjit Singh of the Medical University of South Carolina to study the use of Lovastatin in the treatment of myelin disorders. The drug corrects the biochemical defect of adrenoleukodystrophy, lowering the levels of very long chain fatty acids in plasma. Preliminary studies with an animal model of MS have confirmed Lovastatin's ability to block the induction of cytokines, substances responsible for the inflammation of the CNS. We know that the levels of very long chain fatty acids and of some cytokines are elevated in autism. I am wonderijng already if Lovastatin might be worth trying for children with documented elevated very long chain fatty acids and elevated cytokines.

These studies present exciting possibilities for the future for treating neurodegenerative diseases. They may eventually have relevence for such diverse conditions as autism, cerebral palsy, and CNS vaccine damage syndromes. Time will tell.

Read the original here:
Live Cell & Stem Cell Therapy - healing-arts.org

Read More...

Cell therapy – Institute of Cell Therapy

August 4th, 2016 9:40 am

About cell therapy

Cell therapy is a new official direction in medicine, based on the use of regenerative potential of the adult stem cells, aimed at the treatment of a variety of serious diseases, rehabilitation of patients after injuries and fighting with the premature signs of aging. Stem cells are also considered to be the promising biological material for the creation of the prosthetic heart valves, blood vessels, trachea, they are also used as the unique biofiller for the reconstitution of bone defects and other purposes of the plastic and reconstructive surgery.

The scientists explain the regenerative mechanism of action of stem cells both by their ability to transform into the cells of blood, liver, myocardium, bone, cartilage or nervous tissue and thus restore damaged organs and also by the reovery of the functional activity of the other cells (through the so-called paracrine type) by means of the production of a variety of growth factors.

For clinical purposes, in most cases stem cells are obtained from the bone marrow and cord blood, it is also known that the amount of stem cells, sufficient for treatment, can be isolated from the peripheral blood of an adult person, but after pre-stimulation of hematopoiesis. In recent years there is an increasing number of reports worldwide on the clinical application of stem cells, derived from the placenta, adipose tissue, umbilical cord tissue, amniotic fluid, and even pulp of the milk teeth. Depending on the disease, age and condition of the patient, one or another source of stem cells may be preferred. Hematopoietic (blood-forming) stem cells are used for more than 50 years in the treatment of leukemia and lymphomas, and this treatment is commonly known as the bone marrow transplantation, but today hematopoietic stem cells, derived from umbilical cord blood and peripheral blood are more often used in the hematologic clinics of the world. At the same time, for the treatment of traumatic brain and spinal cord injuries, the stimulation of fractures and chronic wounds healing the mesenchymal stem cells are more preferred, being the precursors of the connective tissue. Mesenchymal stem cells are found in big quantity in fatty tissue, placenta, umbilical cord blood, amniotic fluid. Due to the immunosuppressive effects of mesenchymal stem cells, they are also used in the treatment of a variety of autoimmune diseases (multiple sclerosis, ulcerative colitis, Crohns disease, etc.), as well as post-transplantation complications (to prevent the rejection of the transplanted donor organ). For the treatment of cardiovascular diseases, including lower limbs ischemia, the umbilical cord blood is considered to be the most promising, as it contains a special kind of the endothelial progenitor stem cells, which can not be found in any other human tissue.

Cell therapy may be autologous (own cells are used) and allogeneic (donor cells are used). However, it is known that every nucleated cell in the human body has certain immunological characteristics (HLA-phenotype or immune passport), that is why the use of donor stem cells requires immunological compatibility. This fact determines the appropriateness of the banking of the own stem cells, frozen until the person is still young and healthy. In this aspect the human umbilical cord blood has undisputed medical and biological value as the source of several unique lines of stem cells. Collected in the first minutes of life, umbilical cord blood stem cells have the highest potential for proliferation (growth) and directed differentiation.

Stem cell therapy can be applied both intravenously like a drug, and directly into the damaged tissue. In recent years the method of intraosseous transplantation of cord blood stem cells is more widely used, contributing to the more rapid engraftment. Also a method of introducing stem cells directly into the coronary arteries (coronary heart disease, myocardial infarction) was introduced and it is called cellular cardiomyoplasty.

Cell therapy can be carried out both in monotherapy and complementary to the surgical or drug treatment.

Currently stem cells are successfully used in the treatment of about 100 serious diseases, and in some cases this is the only effective treatment.

As a rule, all patients after the treatment with stem cells suspension mark the activation of the functional systems of the body, the normalization of the immune status and metabolism. Patients after a course of cell therapy note the burst of energy, increase of the general vitality, decrease of fatigue and drowsiness, the improvement of appetite, nights sleep, memory on current events, concentration and thinking. After regenerative stem cell therapy the increase of libido in both sexes and sexual potency in men are noted. The normalization of emotional background is also marked, the decrease of depression and increase of the intellectual and creative activity also occur. Cellular therapy also allows to enhance immunity to colds and stress. For example, the administration of a cell suspension leads to increase of the number of white blood cells in cancer patients with chemotherapeutic depression of hematopoiesis from 2 to 5 thousand within two weeks.

Also cell therapy is an effective tool to overcome chronic fatigue syndrome.

Every year about 40 50,000 transplantations of hematopoietic stem cells are perfomed worldwide. In the USA alone over the past 30 years, one million patients have been treated with the autologous stem cells from different sources. And in 2012 the European Association for Bone Marrow Transplantation announced about the millionth patient, who was carried out the transplantation of the peripheral blood stem cells.

In 2010 a sensational message traveled around the world, that the German scientists, using stem cells, cured a patient from AIDS. And in 2012 the scientists Shinya Yamanaka (Japan) and John Gurdon (UK) were awarded the Nobel Prize for their research in the field of stem cells.

Due to the novelty of the methods of cell therapy, as well as the complexity of this approach, which requires the appropriate technologies, laboratory support and adequate training, stem cell therapy in the whole world can be performed only in hospitals, licensed for this type of activity, and according to the protocols, approved by the appropriate regulatory authorities in the health service. One of the most important international organisations, that regulate the investigations and clinical application of stem cells, are the European Association for the Bone Marrow Transplantation (EBMT), EUROCORD, American Association of Blood Banks (AABB), the International Society for Stem Cell Research (ISSCR), the World Association of Bone Marrow Donors (WMDA), Food and Drug Administration (FDA) in the USA.

In recent years, the functioning of stem cell clinic in combination with the cryobank of stem cells is becoming a common practice. The teamwork of physicians, no need for the transportation of the biological material or engaging of the third parties to provide services, all of this help to ensure the highest quality of medical services.

In Ukraine, the Institute of Cell Therapy with its unique laboratory facilities, Cryobank and clinical base, is a leader in the development of the new methods of treatment with the use of stem cells and provides advanced medical services of the highest quality. According to the level of laboratory and technical equipment, the Institute of Cell Therapy is unique both in Ukraine and in neighboring countries.

Institute of Cell Therapy has become the first organisation in Ukraine, which received the right to conduct clinical trials on the use of stem cells (Order of the Ministry of Health of Ukraine 630 On the clinical trials of stem cells, 2008).

And in 2012, the Ministry of Health of Ukraine for the first time in the Union of Independent States approved the methods of treatment, using cell preparations, produced by the biotechnological laboratory of the Institute of Cell Therapy (Pancrostem and Angiostem).

Excerpt from:
Cell therapy - Institute of Cell Therapy

Read More...

Stem Cell Therapy Boca Raton – Stem Cell Treatment by Dr …

August 4th, 2016 9:40 am

You are Here: Home Stem Cell Therapy Stem Cell Therapy Builds New Tissue for More Complete Recovery What is Stem Cell Therapy?

Stem Cell Therapy is also called regenerative therapy, because it uses the bodys most basic raw material, stem cells, to grow or regenerate new cells that the body needs. Stem cells are undifferentiated or unspecialized cells, meaning that they are blanks that can be developed into another type of cell that is required to repair or replace damaged tissue. In the musculoskeletal field, stem cell therapy can stimulate the formation of new bone, cartilage, tendon, ligaments, fat, and fibrous connective tissue.

Stem Cell Therapy creates specialized cells that have a particular life cycle and purpose, like bone or connective tissue. Stem cells can replicate themselves, too, so it is theoretically possible to have an unending supply of these regenerative machines that can then divide and be guided to produce the cells your doctor needs to fulfill specific purposes in your treatment.

It is important to know the credentials and experience of the doctor you select to administer stem cell therapy. Make sure you are consulting a physician certified in regenerative medicine.

Stem cells are now being studied for use in a wide range of conditions, from diabetes, to heart disease, to musculoskeletal disorders, to neurological disorders.

While stem cells can be derived from several sources, the most adaptable are embryonic and amniotic stem cells, the former derived from days-old human embryos, and the latter derived from the amniotic fluid surrounding a fetus.

Adult stem cells are most often used to produce new cells of the same lineage. The body uses these cells naturally to maintain and repair the tissue in which the stem cells develop.

Induced pluripotent stem cells are adult stem cells that have been genetically programmed to act like embryonic stem cells. These are important tools in evaluating new drugs and in modeling diseases to help researchers understand how disease develops in the body.

Advanced PRP & Stem Cell Therapy Center of Boca Raton is proud to be one of the few practices in the country to have a robust practice surrounding the use of amniotic stem cells. Dr. Berkowitz has developed his reputation as a cellular therapy expert, and the practice has invested in the equipment that can safely store these fragile cells for up to six months.

At Advanced PRP & Stem Cell Therapy Center of Boca Raton, we carefully evaluate patients to determine whether advanced stem cell therapy is a good option for relieving their pain and restoring damaged tissue.

A good candidate for stem cell therapy is a patient whose has mild to moderate osteoarthritis, tendon inflammation, a partial tear of the Achilles tendon, or muscle strain or sprain.

Stem cell therapy is not a first line treatment for wound healing; growth factors like PRP are often an excellent choice for this purpose.

Prolotherapy Steroid injections

Do not take over-the-counter medications that can thin your blood (aspirin, Motrin, Aleve Advil, Naproxen, etc.). Drink as much water as possible on the day of your injection. Arrange for someone to drive you home after treatment.

You will be numb for an hour or two at the injection site, and may experience much more soreness than usual for the first few days after treatment. After the numbness wears off, refrain from any activities that increase your discomfort, and refrain from taking anti-inflammatory medications for at least four weeks after treatment. Control your pain with acetaminophen (Tylenol) or medications that your doctor prescribes. Use ice sparingly, for up to 20 minutes at a time every two to three hours. Resume any physical therapy regimen about a week after treatment.

Your recovery time will depend on the specific condition that is being treated. In all cases, the stem cell injections at the site of your injury will need time to grow your new cells. As the regeneration of new cells proceeds, you should notice a gradual improvement in your level of discomfort, and in your range of motion.

Frequently Asked Questions

It is an advanced technique for helping your body produce the cells it needs to regenerate, repair, and restore damaged or missing tissue. It can involve the use of donor amniotic or embryonic stem cells, which have the ability to develop into any type of cell needed (blood, bone, muscle, organ, tendon, ligaments, connective tissue, []

There may be some pressure at the injection site, but the process is fairly quick. You will be giving a numbing agent to help maintain comfort during your treatment.

Read this article:
Stem Cell Therapy Boca Raton - Stem Cell Treatment by Dr ...

Read More...

Stem cell treatment – Medical Services – Bumrungrad …

August 4th, 2016 9:40 am

What are stem cells?

Our bodies are made up of millions of cells. Most of these cells are specialized to particular locations and functions. The cells in your brain are different from those in your stomach. Heart muscle cells are different from bone cells. And so on.

If a part of the body needs repair, tissue of the same types of cells may be used. Two well-known examples are grafts and transplants. A piece of blood vessel or bone may be grafted from one part of the body to repair another. Or an entire organ may be transplanted to replace a defective organ.

Stem cells are a promising new approach to repairing diseased or defective tissue. Unlike other cells, stem cells are generally not yet specialized. They are like generic blank cells that can be adapted and reproduced according to what they are needed for. Imagine being able to grow replacement tissues that match a patients damaged bone, muscle, or brain cells! This gives you an idea how stem cells might work, and why people are so excited about their potential.

Currently there are a few medical applications of stem cells that have been proven effective and are in use at Bumrungrad and other advanced hospitals. Other stem cell applications are the subject of research and clinical trials around the world. Despite the vast potential for stem cells, there are several issues that need further study. For example, factors and mechanisms of how stem cells differentiate into specific tissue and organs are not yet clearly understood.

What are the potential uses for stem cells?

There are a variety of diseases and injuries in which a patients cells or tissues are destroyed and must be replaced by tissue or organ transplants. Stem cells may be able to generate brand new tissue in these cases, and even cure diseases for which there is currently no adequate therapy. Conditions that could see revolutionary advances from stem cell treatment at some point in the future include Alzheimers, Parkinsons, diabetes, spinal cord injuries, some heart diseases, stroke, arthritis, cancer, and burns.

Stem cells may also prove valuable in genetic and pharmaceutical research.

What benefits of stem cells have been proven?

Stem cell therapy has proven useful in the treatment of certain cancers and diseases of the blood such as leukemia, Thalassemia, and certain immune deficiency diseases.

Stem cells in these cases can help restore the production of blood cells by the body. Blood cells are produced and developed by bone marrow, the soft tissue inside bones. The bodys ability to supply itself with enough normal blood cells can be affected by blood diseases and blood cancers. Blood cell production can also be damaged as a side effect of chemotherapy or radiotherapy in cancer treatment. Stem cells harvested from bone marrow or processed from circulating blood can help offset this damage.

While it is a widely accepted treatment, bone marrow transplantation remains a risky procedure with many potential complications. It has always been reserved for patients with life-threatening diseases.

How is stem cell treatment regulated in Thailand?

Before 2009, there was no specific regulation governing scientists researching human stem cell applications in Thailand. Existing Thai FDA regulations do not cover stem cells because they are not a food or drug.

To correct this lack of oversight, on 27 March 2009, the Thai Food and Drug Administration (Thai FDA) announced that stem cells and their products will be regulated as drugs. The regulations will not cover the use of stem cells in recognized, proven treatments for hematological (blood) diseases. However, for other kinds of treatments, healthcare providers and researchers should follow accepted research practices, including approval from scientific and ethics committees at institutional and national levels.

Additionally, the Thai Medical Council will soon issue parallel regulations to cover the use of stem cells by physicians. For experimental stem cell treatments, practitioners must register and comply with Council criteria.

Institutions must clearly inform patients of the unproven nature of the treatment. Patients must be able to weigh the risks and benefits of such treatment , in the absence of inducement, coercion, or profit motive. Several good studies of stem cell treatments are being conducted under these conditions in Europe and the US.

What is Bumrungrad Internationals position?

Bumrungrad International is optimistic about the future potential of stem cells to treat various diseases. Where stem cell treatments have been proven effective in clinical studies for example in the hematological diseases mentioned previously Bumrungrad offers expert treatment by experienced physicians. In other stem cell applications, our doctors are following international clinical trials closely to determine if and when treatments prove safe and effective.

We will develop capabilities and offer such treatments to our patients when they are accepted by the international medical community. If our clinical research program does participate in any trials, we assure our patients of the following:

Experimental treatments must be approached very cautiously, especially when they are sought by families as a last chance treatment for loved ones in critical condition. Patients and their families must be able to trust that their doctors and hospital have evidence supporting such treatment. The evidence cannot be merely that some patients seem to have benefited from the treatment. It must be subject to the stricter rules of scientific inquiry.

Original post:
Stem cell treatment - Medical Services - Bumrungrad ...

Read More...

Regenerative Cell Institute Las Vegas | Stem Cell Therapy

August 4th, 2016 9:40 am

Welcome to the Most Advanced Regenerative Medical Practice Welcome to the Regenerative Cell Institute!

Regenerative medicine is revolutionizing the way we practice medicine and the Regenerative Cell Institute of Las Vegas, Nevada, is leading the way! Dr. Crispino Santos is a pioneer of regenerative medicine and his expertise in stem cell therapy and stem cell extraction techniques enables him to offer the most innovative stem cell therapy procedures and platelet rich plasma (PRP) treatments to heal the body, naturally rejuvenate tissue, and prevent disease.

Regenerative Cell Institute specializes in minimally invasive stem cell therapy and PRP treatments for pain management, joint pain, spinal pain, and aesthetic procedures.

As a relatively new and rapidly evolving field of interventional pain management, regenerative medicine uses adult stem cells to help the body regenerate, rebuild, and heal itself.

Regenerative Cell Institute (RCI) specializes in all areas of regenerative medicine, using the most advanced stem cell extraction methods and proprietary concentration techniques to deliver the best stem cell therapy and platelet rich plasma (PRP) treatments and ensure patients receive the highest level of care.

When Was The Last Time You Felt Fantastic? Experience Regenerative & Restorative Solutions Today!

Read more here:
Regenerative Cell Institute Las Vegas | Stem Cell Therapy

Read More...

Page 1,112«..1020..1,1111,1121,1131,114..1,1201,130..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick